

**Gerald Bronfman Department of Oncology Annual Report 2019**  
**Publications**

**Bassam Abdulkarim**

1. Sharifi Z, **Abdulkarim B**, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. *Clin Cancer Res*. 2019 Dec 15;25(24):7594-7608. doi: 10.1158/1078-0432.CCR-19-0955. Epub 2019 Sep 20.
2. Chaddad A, Daniel P, Sabri S, Desrosiers C, **Abdulkarim B**. Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma. *Cancers (Basel)*. 2019 Aug 10;11(8). pii: E1148. doi: 10.3390/cancers11081148.
3. Chaddad A, Kucharczyk MJ, Daniel P, Sabri S, Jean-Claude BJ, Niazi T, **Abdulkarim B**. Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation. *Front Oncol*. 2019 May 21;9:374. doi: 10.3389/fonc.2019.00374. eCollection 2019. Review.
4. Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, **Abdulkarim B**, Deschenes J, Torres J, Ursini-Siegel J, Basik M, Koromilas AE. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. *Nat Commun*. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.
5. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, **Abdulkarim BS**. Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities. *Front Oncol*. 2019 Feb 4;9:41. doi: 10.3389/fonc.2019.00041. eCollection 2019. Review.
6. Chaddad A, Daniel P, Desrosiers C, Toews M, **Abdulkarim B**. Novel Radiomic Features Based on Joint Intensity Matrices for Predicting Glioblastoma Patient Survival Time. *IEEE J Biomed Health Inform*. 2019 Mar;23(2):795-804. doi: 10.1109/JBHI.2018.2825027. Epub 2018 Apr 9.

**Sharon Abish**

1. Lauhasurayotin S, Cuvelier GD, Klaassen RJ, Fernandez CV, Pastore YD, **Abish S**, Rayar M, Steele M, Jardine L, Breakey VR, Brossard J, Sinha R, Silva M, Goodyear L, Lipton JH, Michon B, Corriveau-Bourque C, Sung L, Shabanova I, Li H, Zlateska B, Dhanraj S, Cada M, Scherer SW, Dror Y. Reanalysing genomic data by normalized coverage values uncovers CNVs in bone marrow failure gene panels. *NPJ Genom Med*. 2019 Dec 9;4:30. doi: 10.1038/s41525-019-0104-9. eCollection 2019.
2. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, **Abish S**, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, Foulkes WD, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N. Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with

hemophagocytic lymphohistiocytic syndrome. *Nat Genet.* 2019 Jan;51(1):196. doi: 10.1038/s41588-018-0304-8.

3. Ma J, Siminoski K, Alos N, Halton J, Ho J, Cummings EA, Shenouda N, Matzinger MA, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis VA, Laverdière C, Israels S, Grant RM, Fernandez CV, Dix DB, Couch R, Cairney E, Barr R, Atkinson S, **Abish S**, Moher D, Rauch F, Ward LM; Canadian STOPP Consortium. Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia. *J Clin Endocrinol Metab.* 2019 Feb 1;104(2):213-222. doi: 10.1210/jc.2018-01083.

### **Jason Agulnik**

1. Bebb DG, **Agulnik J**, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS. Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. *Curr Oncol.* 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.
2. Wang H, **Agulnik J**, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, Spatz A. Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [*Lung Cancer* 132 (June) (2019) 36-38]. *Lung Cancer.* 2019 Oct;136:161. doi: 10.1016/j.lungcan.2019.08.016. Epub 2019 Aug 25. No abstract available.
3. Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, Batist G, **Agulnik J**. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. *Mol Cancer Ther.* 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.
4. Wang H, **Agulnik J**, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, Spatz A. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. *Lung Cancer.* 2019 Jun;132:36-38. doi: 10.1016/j.lungcan.2019.04.009. Epub 2019 Apr 8. Erratum in: *Lung Cancer.* 2019 Oct;136:161.

### **Moulay Alaoui-Jamali**

1. Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, **Alaoui-Jamali M**, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res.* 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.

2. Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, **Alaoui-Jamali MA**, Foulkes WD, Witcher M. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. *Cancer Res.* 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.
3. Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, Qiu D, Asslan M, **Alaoui-Jamali MA**. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. *Autophagy.* 2019 Aug;15(8):1376-1390. doi: 10.1080/15548627.2019.1582951. Epub 2019 Mar 1.
4. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, **Alaoui-Jamali M**, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma *In Situ*. *Cancer Res.* 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
5. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, **Alaoui-Jamali M**, Witcher M. Oncogenic activity of poly (ADP-ribose) glycohydrolase. *Oncogene.* 2019 Mar;38(12):2177-2191. doi: 10.1038/s41388-018-0568-6. Epub 2018 Nov 20.
6. da Silva SD, Xu B, Maschietto M, Marchi FA, Alkailani MI, Bijian K, Xiao D, **Alaoui-Jamali MA**. TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis. *Mol Cancer Ther.* 2019 Jan;18(1):139-146. doi: 10.1158/1535-7163.MCT-17-1261. Epub 2018 Oct 29.

### Thierry Alcindor

1. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, **Alcindor T**, Colomer R. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatology.* 2019 Dec 14. pii: S1424-3903(19)30807-5. doi: 10.1016/j.pan.2019.12.010. [Epub ahead of print]
2. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, **Alcindor T**, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet.* 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.
3. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, **Alcindor T**, Colomer R. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. *Pancreas.* 2019 May/Jun;48(5):e45-e47. doi: 10.1097/MPA.0000000000001294. No abstract available.

4. **Alcindor T**, Al-Fakeeh A, Goulding K, Solymoss S, Ste-Marie N, Turcotte R. Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study. *Oncologist*. 2019 Mar;24(3):e111-e114. doi: 10.1634/theoncologist.2018-0081. Epub 2018 Sep 26.

#### **Joanne Alfieri**

1. Fawaz ZS, Posel N, Royal-Preyra BT, Khriguian J, **Alfieri J**. Creation and Pilot-testing of Virtual Patients for Learning Oncologic Emergency Management. *Cureus*. 2019 Nov 20;11(11):e6206. doi: 10.7759/cureus.6206.
2. Leung E, D'Souza D, Bachand F, Han K, **Alfieri J**, Huang F, Vigneault E, Barkati M, Wiebe EM, Foster W, Fortin I, Velker V, Bowes D, Barnes E, Patil N, Banerjee R, Barbera L, Ravi A. MRI-based interstitial brachytherapy for vaginal tumors: A multi-institutional study on practice patterns, contouring, and consensus definitions of target volumes. *Brachytherapy*. 2019 Sep - Oct;18(5):598-605. doi: 10.1016/j.brachy.2019.05.007. Epub 2019 Jun 21.
3. Tsui JMG, Grewal NKS, Sivapragasam M, Flanagan M, Golden DW, **Alfieri J**, Mattes MD. Tumor Board Shadowing: A Unique Approach for Integrating Radiation Oncologists Into General Medical Student Education. *Int J Radiat Oncol Biol Phys*. 2019 Jul 15;104(4):773-777. doi: 10.1016/j.ijrobp.2019.03.042. Epub 2019 Apr 3.
4. Lucia F, Visvikis D, Vallières M, Desseroit MC, Miranda O, Robin P, Bonaffini PA, **Alfieri J**, Masson I, Mervoyer A, Reinhold C, Pradier O, Hatt M, Schick U. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. *Eur J Nucl Med Mol Imaging*. 2019 Apr;46(4):864-877. doi: 10.1007/s00259-018-4231-9. Epub 2018 Dec 7.
5. Albeesh R, Turgeon GA, **Alfieri J**, Mansure JJ, Fu L, Arseneau J, Zeng X, Jardon K, Gilbert L, Souhami L. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. *Gynecol Oncol*. 2019 Jan;152(1):26-30. doi: 10.1016/j.ygyno.2018.11.002. Epub 2018 Nov 22.

#### **Raquel Aloyz**

1. Sharif-Askari B, Doyon D, Paliouras M, **Aloyz R**. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. *Sci Rep*. 2019 Jul 30;9(1):11069. doi: 10.1038/s41598-019-47305-2.
2. Galicia-Vázquez G, **Aloyz R**. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? *Crit Rev Oncol Hematol*. 2019 Feb;134:65-70. doi: 10.1016/j.critrevonc.2018.12.003. Epub 2018 Dec 19. Review.

#### **Armen Aprikan**

1. Wissing MD, Kassouf W, Tanguay S, **Aprikian AG**. The use of perioperative chemotherapy in patients undergoing radical cystectomy for bladder cancer in Quebec (Canada), 2000-2016. *Can Urol Assoc J*. 2019 Nov 29. doi: 10.5489/cuaj.6094. [Epub ahead of print]
2. Saad F, **Aprikian A**, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J*. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136. No abstract available.

3. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, **Aprikian A**, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderma van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *Eur Urol*. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.
4. Saad F, **Aprikian A**, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J*. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.
5. Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, Cury FL, Tanguay S, **Aprikian AG**, Kassouf W, Chevalier S. Improving ultrasound-based prostate volume estimation. *BMC Urol*. 2019 Jul 24;19(1):68. doi: 10.1186/s12894-019-0492-2.
6. Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoeye N, Latour M, **Aprikian A**, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network. Validation of the prognostic value of NF- $\kappa$ B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. *PLoS Med*. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.
7. Klil-Drori AJ, Santella C, Tascilar K, Yin H, **Aprikian A**, Azoulay L. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study. *Drug Saf*. 2019 Aug;42(8):1005-1011. doi: 10.1007/s40264-019-00847-w.
8. Minnella EM, Awasthi R, Bousquet-Dion G, Ferreira V, Austin B, Audi C, Tanguay S, **Aprikian A**, Carli F, Kassouf W. Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial. *Eur Urol*

- Focus. 2019 Jun 8. pii: S2405-4569(19)30153-1. doi: 10.1016/j.euf.2019.05.016. [Epub ahead of print]
9. Hu J, **Aprikian AG**, Vanhuysse M, Dragomir A. Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. *J Oncol Pract*. 2019 Jun;15(6):e510-e519. doi: 10.1200/JOP.18.00626. Epub 2019 May 20.
  10. Lahcene H, **Aprikian AG**, Vanhuysse M, Hu J, Bladou F, Cury F, Kassouf W, Perreault S, Dragomir A. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. *J Oncol Pharm Pract*. 2019 Apr 18:1078155219842329. doi: 10.1177/1078155219842329. [Epub ahead of print]
  11. Wissing MD, Santos F, Zakaria AS, O'Flaherty A, Tanguay S, Kassouf W, **Aprikian AG**. Short- and long-term survival has improved after radical cystectomy for bladder cancer in Québec during the years 2000-2015. *J Surg Oncol*. 2019 Jun;119(8):1135-1144. doi: 10.1002/jso.25456. Epub 2019 Mar 28.
  12. Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, **Aprikian A**. Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada. *Psychooncology*. 2019 Apr;28(4):839-846. doi: 10.1002/pon.5031. Epub 2019 Feb 27.
  13. Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, **Aprikian A**, Saad F, Carmel M, Chevalier S, Guillemette C. A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. *Cancer Epidemiol Biomarkers Prev*. 2019 Apr;28(4):701-706. doi: 10.1158/1055-9965.EPI-18-1002. Epub 2019 Feb
  14. Bramhecha YM, Rouzbeh S, Guérard KP, Scarlata E, Brimo F, Chevalier S, Hamel L, **Aprikian AG**, Lapointe J. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. *Mod Pathol*. 2019 Jan;32(1):128-138. doi: 10.1038/s41379-018-0107-6. Epub 2018 Aug 23.
  15. Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, **Aprikian A**. The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. *World J Urol*. 2019 May;37(5):789-798. doi: 10.1007/s00345-018-2457-6. Epub 2018 Aug 22.
  16. Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, **Aprikian A**. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. *BJU Int*. 2019 Apr;123(4):624-631. doi: 10.1111/bju.14512. Epub 2018 Sep 11.
  17. Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, **Aprikian AG**, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI. A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. *Pathol Oncol Res*. 2019 Jul;25(3):979-986. doi: 10.1007/s12253-018-0408-6. Epub 2018 Apr 6.

### Sylvie Aubin

1. Aubin S, Rosberger Z, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young

Adults with Cancer. *J Adolesc Young Adult Oncol.* 2019 Apr;8(2):172-189. doi: 10.1089/jayao.2017.0101. Epub 2018 Nov 28.

### Laurent Azoulay

1. Pradhan R, Yin H, Yu OHY, **Azoulay L**. The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. *Drug Saf.* 2019 Dec 14. doi: 10.1007/s40264-019-00892-5. [Epub ahead of print]
2. Baumfeld Andre E, Reynolds R, Caubel P, **Azoulay L**, Dreyer NA. Trial designs using real-world data: The changing landscape of the regulatory approval process. *Pharmacoepidemiol Drug Saf.* 2019 Dec 10. doi: 10.1002/pds.4932. [Epub ahead of print] Review.
3. Pradhan R, Montastruc F, Rousseau V, Patorno E, **Azoulay L**. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. *Lancet Diabetes Endocrinol.* 2020 Jan;8(1):13-14. doi: 10.1016/S2213-8587(19)30382-1. Epub 2019 Dec 2. No abstract available.
4. Huang TY, Welch EC, Shinde MU, Platt RW, Filion KB, **Azoulay L**, Maro JC, Platt R, Toh S. Reproducing Protocol-Based Studies Using Parameterizable Tools-Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. *Clin Pharmacol Ther.* 2019 Oct 20. doi: 10.1002/cpt.1698. [Epub ahead of print]
5. Secrest MH, **Azoulay L**, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, Filion KB. A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29 Suppl 1:86-92. doi: 10.1002/pds.4878. Epub 2019 Aug 28.
6. Renoux C, **Azoulay L**, Dell'Aniello S, Yu OHY. The Reply. *Am J Med.* 2019 Oct;132(10):e749. doi: 10.1016/j.amjmed.2019.06.010. Epub 2019 Jul 26. No abstract available.
7. Abrahami D, Douros A, Yin H, Yu OHY, **Azoulay L**. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. *Diabetes Care.* 2019 Sep;42(9):e150-e152. doi: 10.2337/dc19-0849. Epub 2019 Jul 11. No abstract available.
8. Filion KB, Douros A, **Azoulay L**, Yin H, Yu OH, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. *Br J Clin Pharmacol.* 2019 Oct;85(10):2378-2389. doi: 10.1111/bcp.14056. Epub 2019 Jul 31.
9. Klil-Drori AJ, Santella C, Tascilar K, Yin H, Aprikian A, **Azoulay L**. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study. *Drug Saf.* 2019 Aug;42(8):1005-1011. doi: 10.1007/s40264-019-00847-w.
10. Douros A, Rouette J, Yin H, Yu OHY, Filion KB, **Azoulay L**. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. *Diabetes Care.* 2019 Aug;42(8):1496-1503. doi: 10.2337/dc19-0409. Epub 2019 Jun 10.
11. Santella C, Renoux C, Yin H, Yu OHY, **Azoulay L**. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism. *Am J Epidemiol.* 2019 Sep 1;188(9):1666-1673. doi: 10.1093/aje/kwz138.

12. Loo SY, **Azoulay L**, Nie R, Dell'Aniello S, Yu OHY, Renoux C. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study. *Am J Med.* 2019 Sep;132(9):1069-1077.e4. doi: 10.1016/j.amjmed.2019.03.022. Epub 2019 Apr 3.
13. Rotshild V, **Azoulay L**, Feldhamer I, Perlman A, Muszkat M, Matok I. Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population-Based Nested Case-Control Study. *Pharmacotherapy.* 2019 Jun;39(6):690-696. doi: 10.1002/phar.2266. Epub 2019 Apr 17. Erratum in: *Pharmacotherapy.* 2019 Sep;39(9):964.
14. Loo SY, Vutcovici M, Bitton A, Lakatos PL, **Azoulay L**, Suissa S, Brassard P. Risk of Malignant Cancers in Inflammatory Bowel Disease. *J Crohns Colitis.* 2019 Sep 27;13(10):1302-1310. doi: 10.1093/ecco-jcc/jjz058.
15. Douros A, Renoux C, Yin H, Filion KB, Suissa S, **Azoulay L**. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. *Am J Med.* 2019 Feb;132(2):191-199.e12. doi: 10.1016/j.amjmed.2018.10.008. Epub 2018 Oct 25.
16. Klil-Drori AJ, Yin H, **Azoulay L**, Harnois M, Gratton MO, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. *Haematologica.* 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10. No abstract available.
17. Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Racah B, Horwitz E, Aldouby-Bier G, Negev T, Matok I, **Azoulay L**, Kalish Y, Muszkat M. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. *J Thromb Thrombolysis.* 2019 May;47(4):590-595. doi: 10.1007/s11239-018-01804-7.
18. Montastruc F, Renoux C, Dell'Aniello S, Simon TA, **Azoulay L**, Hudson M, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology (Oxford).* 2019 Apr 1;58(4):683-691. doi: 10.1093/rheumatology/key352.

### **Boris Bahoric**

1. Elakshar S, Tsui JMG, Kucharczyk MJ, Tomic N, Fawaz ZS, **Bahoric B**, Papayanatos J, Chaddad A, Niazi T. Does Interfraction Cone Beam Computed Tomography Improve Target Localization in Prostate Bed Radiotherapy? *Technol Cancer Res Treat.* 2019 Jan 1;18:1533033819831962. doi: 10.1177/1533033819831962. Erratum in: *Technol Cancer Res Treat.* 2019 Jan 1;18:1533033819846992.
2. Francis JA, Eiriksson L, Dean E, Sebastianelli A, **Bahoric B**, Salvador S. No. 370- Management of Squamous Cell Cancer of the Vulva. *J Obstet Gynaecol Can.* 2019 Jan;41(1):89-101. doi: 10.1016/j.jogc.2018.07.004.
3. Francis JA, Eiriksson L, Dean E, Sebastianelli A, **Bahoric B**, Salvador S. No 370 - Prise en charge du cancer spinocellulaire de la vulve. *J Obstet Gynaecol Can.* 2019 Jan;41(1):102-115. doi: 10.1016/j.jogc.2018.11.016. Erratum in: *J Obstet Gynaecol Can.* 2019 Apr;41(4):575.



**Mark Basik**

1. Morency D, Dumitra S, Parvez E, Martel K, **Basik M**, Robidoux A, Poirier B, Holloway CMB, Gaboury L, Sideris L, Meterissian S, Boileau JF. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. *Ann Surg Oncol*. 2019 Dec;26(13):4337-4345. doi: 10.1245/s10434-019-07809-7. Epub 2019 Oct 11.
2. Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, **Basik M**. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res*. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.
3. Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak M, Ferrario C, **Basik M**. Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. *Clin Cancer Res*. 2019 Dec 1;25(23):7229-7242. doi: 10.1158/1078-0432.CCR-19-1268. Epub 2019 Sep 12.
4. Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, **Basik M**. Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. *Front Oncol*. 2019 Aug 6;9:698. doi: 10.3389/fonc.2019.00698. eCollection 2019.
5. Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, **Basik M**, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. *Nat Commun*. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.
6. Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, Greenwood CMT, **Basik M**, Muanza TM. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. *Sci Rep*. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.
7. Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, **Basik M**, Koromilas AE. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. *Nat Commun*. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.
8. Cavallone L, Aldamry M, Lafleur J, Lan C, Gonzalez Ginestet P, Alirezaie N, Ferrario C, Aguilar-Mahecha A, **Basik M**. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR. *Cancer Epidemiol Biomarkers Prev*. 2019 May;28(5):909-916. doi: 10.1158/1055-9965.EPI-18-0586. Epub 2019 Mar

9. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, **Basik M**, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. *Cancer Res.* 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.

### Gerald Batist

1. Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, **Batist G**, Borchers CH. Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. *Cancers (Basel).* 2019 Dec 1;11(12). pii: E1907. doi: 10.3390/cancers11121907.
2. Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, **Batist G**, Borchers CH. Targeted and Untargeted Proteomics Approaches in Biomarker Development. *Proteomics.* 2019 Nov 15:e1900029. doi: 10.1002/pmic.201900029. [Epub ahead of print] Review.
3. Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, **Batist G**, Basik M. Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report. *Front Oncol.* 2019 Aug 6;9:698. doi: 10.3389/fonc.2019.00698. eCollection 2019.
4. Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, **Batist G**, Agulnik J. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. *Mol Cancer Ther.* 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.
5. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, **Batist G**, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nat Med.* 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.

### Nicole Beauchemin

1. Jeyakumar T, Fodil N, Van Der Kraak L, Meunier C, Cayrol R, McGregor K, Langlais D, Greenwood CMT, **Beauchemin N**, Gros P. Inactivation of Interferon Regulatory Factor 1 Causes Susceptibility to Colitis-Associated Colorectal Cancer. *Sci Rep.* 2019 Dec 11;9(1):18897. doi: 10.1038/s41598-019-55378-2.
2. Jeyakumar T, **Beauchemin N**, Gros P. Impact of the Microbiome on the Human Genome. *Trends Parasitol.* 2019 Oct;35(10):809-821. doi: 10.1016/j.pt.2019.07.015. Epub 2019 Aug 23. Review.

### Christoph Borchers

1. Silva F, Guirgis A, von Aderkas P, **Borchers CH**, Thornburg R. LC-MS/MS based comparative proteomics of floral nectars reveal different mechanisms involved in floral

- defense of *Nicotiana* spp., *Petunia hybrida* and *Datura stramonium*. *J Proteomics*. 2020 Feb 20;213:103618. doi: 10.1016/j.jprot.2019.103618. Epub 2019 Dec 14.
- Mohammed Y, Kootte RS, Kopatz WF, **Borchers CH**, Büller HR, Versteeg HH, Nieuwdorp M, van Mens TE. The intestinal microbiome potentially affects thrombin generation in human subjects. *J Thromb Haemost*. 2019 Dec 6. doi: 10.1111/jth.14699. [Epub ahead of print]
  - Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, Batist G, **Borchers CH**. Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. *Cancers (Basel)*. 2019 Dec 1;11(12). pii: E1907. doi: 10.3390/cancers11121907.
  - Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, Batist G, **Borchers CH**. Targeted and Untargeted Proteomics Approaches in Biomarker Development. *Proteomics*. 2019 Nov 15:e1900029. doi: 10.1002/pmic.201900029. [Epub ahead of print] Review.
  - Makepeace KAT, Brodie NI, Popov KI, Gudavicius G, Nelson CJ, Petrotchenko EV, Dokholyan NV, **Borchers CH**. Ligand-induced disorder-to-order transitions characterized by structural proteomics and molecular dynamics simulations. *J Proteomics*. 2020 Jan 16;211:103544. doi: 10.1016/j.jprot.2019.103544. Epub 2019 Nov 1.
  - Popov KI, Makepeace KAT, Petrotchenko EV, Dokholyan NV, **Borchers CH**. Insight into the Structure of the "Unstructured" Tau Protein. *Structure*. 2019 Nov 5;27(11):1710-1715.e4. doi: 10.1016/j.str.2019.09.003. Epub 2019 Oct 15.
  - Martínez de Paz A, Khajavi L, Martin H, Claveria-Gimeno R, Tom Dieck S, Cheema MS, Sanchez-Mut JV, Moksa MM, Carles A, Brodie NI, Sheikh TI, Freeman ME, Petrotchenko EV, **Borchers CH**, Schuman EM, Zytnicki M, Velazquez-Campoy A, Abian O, Hirst M, Esteller M, Vincent JB, Malnou CE, Ausió J. MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2. *Epigenetics Chromatin*. 2019 Oct 10;12(1):63. doi: 10.1186/s13072-019-0298-1.
  - Bhardwaj M, Gies A, Weigl K, Tikk K, Benner A, Schrotz-King P, **Borchers CH**, Brenner H. Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. *Cancers (Basel)*. 2019 Sep 25;11(10). pii: E1426. doi: 10.3390/cancers11101426.
  - Pires ES, Haridoim CCP, Miranda KR, Secco DA, Lobo LA, de Carvalho DP, Han J, **Borchers CH**, Ferreira RBR, Salles JF, Domingues RMCP, Antunes LCM. The Gut Microbiome and Metabolome of Two Riparian Communities in the Amazon. *Front Microbiol*. 2019 Sep 4;10:2003. doi: 10.3389/fmicb.2019.02003. eCollection 2019.
  - Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, **Borchers CH**, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res*. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.

11. Oyama Y, Bartman CM, Bonney S, Lee JS, Walker LA, Han J, **Borchers CH**, Buttrick PM, Aherne CM, Clendenen N, Colgan SP, Eckle T. Intense Light-Mediated Circadian Cardioprotection via Transcriptional Reprogramming of the Endothelium. *Cell Rep.* 2019 Aug 6;28(6):1471-1484.e11. doi: 10.1016/j.celrep.2019.07.020.
12. Parker CE, Warren Hines MRE, Mocanu V, Greer SF, **Borchers CH**. Mass Spectrometric Determination of Protein Ubiquitination. *Methods Mol Biol.* 2019;1934:191-221. doi: 10.1007/978-1-4939-9055-9\_13.
13. Mao F, Liu T, Hou X, Zhao H, He W, Li C, Jing Z, Sui J, Wang F, Liu X, Han J, **Borchers CH**, Wang JS, Li W. Increased sulfation of bile acids in mice and human subjects with sodium taurocholate cotransporting polypeptide deficiency. *J Biol Chem.* 2019 Aug 2;294(31):11853-11862. doi: 10.1074/jbc.RA118.007179. Epub 2019 Jun 14.
14. Larina IM, Percy AJ, Yang J, **Borchers CH**, Nosovsky AM, Grigoriev AI, Nikolaev EN. Publisher Correction: Protein expression changes caused by spaceflight as measured for 18 Russian cosmonauts. *Sci Rep.* 2019 Jun 7;9(1):8570. doi: 10.1038/s41598-019-43121-w.
15. Brodie NI, Popov KI, Petrotchenko EV, Dokholyan NV, **Borchers CH**. Conformational ensemble of native  $\alpha$ -synuclein in solution as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations. *PLoS Comput Biol.* 2019 Mar 27;15(3):e1006859. doi: 10.1371/journal.pcbi.1006859. eCollection 2019 Mar.
16. Kashirina DN, Percy AJ, Pastushkova LK, **Borchers CH**, Kireev KS, Ivanisenko VA, Kononikhin AS, Nikolaev EN, Larina IM. The molecular mechanisms driving physiological changes after long duration space flights revealed by quantitative analysis of human blood proteins. *BMC Med Genomics.* 2019 Mar 13;12(Suppl 2):45. doi: 10.1186/s12920-019-0490-y.
17. Teixeira F, Tse E, Castro H, Makepeace KAT, Meinen BA, **Borchers CH**, Poole LB, Bardwell JC, Tomás AM, Southworth DR, Jakob U. Chaperone activation and client binding of a 2-cysteine peroxiredoxin. *Nat Commun.* 2019 Feb 8;10(1):659. doi: 10.1038/s41467-019-08565-8.
18. Anwar MA, Dai DL, Wilson-McManus J, Smith D, Francis GA, **Borchers CH**, McManus BM, Hill JS, Cohen Freue GV. Multiplexed LC-ESI-MRM-MS-based Assay for Identification of Coronary Artery Disease Biomarkers in Human Plasma. *Proteomics Clin Appl.* 2019 Jul;13(4):e1700111. doi: 10.1002/prca.201700111. Epub 2019 Jan 28.
19. Shultis D, Mitra P, Huang X, Johnson J, Khattak NA, Gray F, Piper C, Czajka J, Hansen L, Wan B, Chinnaswamy K, Liu L, Wang M, Pan J, Stuckey J, Cierpicki T, **Borchers CH**, Wang S, Lei M, Zhang Y. Changing the Apoptosis Pathway through Evolutionary Protein Design. *J Mol Biol.* 2019 Feb 15;431(4):825-841. doi: 10.1016/j.jmb.2018.12.016. Epub 2019 Jan 6.
20. Wang R, Sheps JA, Liu L, Han J, Chen PSK, Lamontagne J, Wilson PD, Welch I, **Borchers CH**, Ling V. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in *Mdr2*<sup>-/-</sup> mice. *J Lipid Res.* 2019 Jan;60(1):85-97. doi: 10.1194/jlr.M088070. Epub 2018 Nov 11.

### Nathanial Bouganim

1. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, **Bouganim N**, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological

- outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatology*. 2019 Dec 14. pii: S1424-3903(19)30807-5. doi: 10.1016/j.pan.2019.12.010. [Epub ahead of print]
2. Sadeghi N, Khalife S, Mascarella MA, Ramanakumar AV, Richardson K, Joshi AS, **Bouganim N**, Taheri R, Fuson A, Siegel R. Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. *Head Neck*. 2019 Nov 27. doi: 10.1002/hed.26022. [Epub ahead of print]
  3. Dankner M, Senecal J, Neubarth NS, Bertos N, Park M, Issa-Chergui B, Asselah J, Siegel PM, **Bouganim N**. A survey of health care professionals and oncology patients at the McGill University Health Centre reveals enthusiasm for establishing a postmortem rapid tissue donation program. *Curr Oncol*. 2019 Aug;26(4):e558-e570. doi: 10.3747/co.26.4771. Epub 2019 Aug 1.
  4. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, **Bouganim N**, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. *Pancreas*. 2019 May/Jun;48(5):e45-e47. doi: 10.1097/MPA.0000000000001294. No abstract available.
  5. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, **Bouganim N**, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with  $\geq 25\%$  tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. *Eur J Cancer*. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

### **Pnina Brodt**

1. Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, **Brodt P**, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. *J Hepatol*. 2019 Dec 31. pii: S0168-8278(19)30761-5. doi: 10.1016/j.jhep.2019.12.016. [Epub ahead of print]
2. Milette S, Hashimoto M, Perrino S, Qi S, Chen M, Ham B, Wang N, Istomine R, Lowy AM, Piccirillo CA, **Brodt P**. Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. *Nat Commun*. 2019 Dec 17;10(1):5745. doi: 10.1038/s41467-019-13571-x.

### **Julia Burnier**

1. Bustamante P, Miyamoto D, Goyeneche A, de Alba Graue PG, Jin E, Tsering T, Dias AB, Burnier MN, **Burnier JV**. Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma. *Cancer Med*. 2019 Dec;8(17):7265-7277. doi: 10.1002/cam4.2594. Epub 2019 Oct 7.
2. Bergeron S, Miyamoto D, Sanft DM, **Burnier JV**, Mastromonaco C, Romano AA, Arthurs B, Burnier MN Jr.,. Novel application of anterior segment optical coherence tomography for periocular imaging. *Can J Ophthalmol*. 2019 Aug;54(4):431-437. doi: 10.1016/j.jcjo.2018.09.007. Epub 2018 Nov 28.

3. Moreira-Neto CA, Bergeron S, Coblentz J, Zoroquiain P, Maloney S, Mastromonaco C, Esposito E, Romano A, Belfort Neto R, Moreira CA Jr, **Burnier JV**, Burnier M Jr. Optimizing optical coherence tomography and histopathology correlation in retinal imaging. *Can J Ophthalmol*. 2019 Apr;54(2):280-287. doi: 10.1016/j.jcjo.2018.06.024. Epub 2018 Aug 27.

#### **Stephen Caplan**

1. Patriquin CJ, Kiss T, **Caplan S**, Chin-Yee I, Grewal K, Grossman J, Larratt L, Marceau D, Nevill T, Sutherland DR, Wells RA, Leber B. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. *Eur J Haematol*. 2019 Jan;102(1):36-52. doi: 10.1111/ejh.13176. Epub 2018 Oct 25. Review.

#### **Prosanto Chaudhury**

1. Urbach, DR, Karimuddin AA, Wei A, Zabolotny BP, Lefebvre G, Walsh M, Hameed M, Fata P, **Chaudhury P**, McLeod RS, Cleary SP. A Canadian strategy for surgical quality improvement. *Can J Surg*. 2019 Dec 1;62(6):E16-E18. doi: 10.1503/cjs.019318.
2. Hashim A, Bessissow A, Valenti D, **Chaudhury P**, Barkun A, Waschke K, Chen YI. Endoscopic ultrasound-guided biliary drainage in high grade biliary hilar obstruction. *Endoscopy*. 2019 Oct;51(10):E284-E285. doi: 10.1055/a-0836-2514. Epub 2019 May 23. No abstract available.

#### **Robin Cohen**

1. **Cohen SR**, Russell LB, Leis A, Shahidi J, Porterfield P, Kuhl DR, Gadermann AM, Sawatzky R. More comprehensively measuring quality of life in life-threatening illness: the McGill Quality of Life Questionnaire - Expanded. *BMC Palliat Care*. 2019 Oct 31;18(1):92. doi: 10.1186/s12904-019-0473-y.
2. Milman E, Neimeyer RA, Fitzpatrick M, MacKinnon CJ, Muis KR, **Cohen SR**. Prolonged grief and the disruption of meaning: Establishing a mediation model. *J Couns Psychol*. 2019 Nov;66(6):714-725. doi: 10.1037/cou0000370.
3. Milman E, Neimeyer RA, Fitzpatrick M, MacKinnon CJ, Muis KR, **Cohen SR**. Rumination moderates the role of meaning in the development of prolonged grief symptomatology. *J Clin Psychol*. 2019 Jun;75(6):1047-1065. doi: 10.1002/jclp.22751. Epub 2019 Feb 22.

#### **Victor Cohen**

1. Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, **Cohen V**, Batist G, Agulnik J. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. *Mol Cancer Ther*. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.

#### **Fabio Cury**

1. Chatterjee A, Serban M, Faria S, Souhami L, **Cury F**, Seuntjens J. Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer

- patients. *Phys Med.* 2020 Jan;69:36-43. doi: 10.1016/j.ejmp.2019.11.023. Epub 2019 Dec 6.
2. Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, **Cury FL**, Tanguay S, Aprikian AG, Kassouf W, Chevalier S. Improving ultrasound-based prostate volume estimation. *BMC Urol.* 2019 Jul 24;19(1):68. doi: 10.1186/s12894-019-0492-2.
  3. Lahcene H, Aprikian AG, Vanhuyse M, Hu J, Bladou F, **Cury F**, Kassouf W, Perreault S, Dragomir A. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. *J Oncol Pharm Pract.* 2019 Apr 18:1078155219842329. doi: 10.1177/1078155219842329. [Epub ahead of print]
  4. Adil K, Popovic M, **Cury FL**, Faria SL, Duclos M, Souhami L. Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. *Pract Radiat Oncol.* 2019 Jan;9(1):24-28. doi: 10.1016/j.prro.2018.07.006. Epub 2018 Aug 7.

### Sonia del Rincon

1. Guo Q, Huang F, Goncalves C, **Del Rincón SV**, Miller WH Jr. Translation of cancer immunotherapy from the bench to the bedside. *Adv Cancer Res.* 2019;143:1-62. doi: 10.1016/bs.acr.2019.03.001. Epub 2019 May 2.
2. Ellederova Z, **Del Rincon S**, Koncicka M, Susor A, Kubelka M, Sun D, Spruck C. CKS1 Germ Line Exclusion Is Essential for the Transition from Meiosis to Early Embryonic Development. *Mol Cell Biol.* 2019 Jun 13;39(13). pii: e00590-18. doi: 10.1128/MCB.00590-18. Print 2019 Jul 1.
3. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, **Del Rincón SV**, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. *Cancer Res.* 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
4. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, **Del Rincon S**, Mackey J, Damaraju S, Alaoui-Jamali M, Witcher M. Oncogenic activity of poly (ADP-ribose) glycohydrolase. *Oncogene.* 2019 Mar;38(12):2177-2191. doi: 10.1038/s41388-018-0568-6. Epub 2018 Nov 20.

### Slobodan Devic

1. **Devic S**, Aldelaijan S, Bekerat H. Impact of inertia on possible fundamental drawbacks in radiochromic film dosimetry. *Phys Med.* 2019 Oct;66:133-134. doi: 10.1016/j.ejmp.2019.08.019. Epub 2019 Sep 26. No abstract available.
2. Aldelaijan S, **Devic S**, Papaconstadopoulos P, Bekerat H, Cormack RA, Seuntjens J, Buzurovic IM. Dose-response linearization in radiochromic film dosimetry based on multichannel normalized pixel value with an integrated spectral correction for scanner response variations. *Med Phys.* 2019 Nov;46(11):5336-5349. doi: 10.1002/mp.13818. Epub 2019 Sep 26.
3. **Devic S**, Liang L, Tomic N, Bekerat H, Morcos M, Popovic M, Watson P, Aldelaijan S, Seuntjens J. Dose measurements nearby low energy electronic brachytherapy sources using radiochromic film. *Phys Med.* 2019 Aug;64:40-44. doi: 10.1016/j.ejmp.2019.05.017. Epub 2019 Jun 22.

4. Kostou T, Papadimitroulas P, Papaconstadopoulos P, **Devic S**, Seuntjens J, Kagadis GC. Size-specific dose estimations for pediatric chest, abdomen/pelvis and head CT scans with the use of GATE. *Phys Med.* 2019 Sep;65:181-190. doi: 10.1016/j.ejmp.2019.08.020. Epub 2019 Sep 5.
5. Garant A, Magnan S, **Devic S**, Martin AG, Boutros M, Vasilevsky CA, Ferland S, Bujold A, DesGroseilliers S, Sebahang H, Richard C, Vuong T. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer. *Int J Radiat Oncol Biol Phys.* 2019 Dec 1;105(5):1005-1011. doi: 10.1016/j.ijrobp.2019.08.042. Epub 2019 Aug 30.
6. Tomic N, Papaconstadopoulos P, Bekerat H, Antunovic G, Aldelaijan S, Seuntjens J, **Devic S**. Monte Carlo simulations of different CT X-ray energy spectra within CTDI phantom and the influence of its changes on radiochromic film measurements. *Phys Med.* 2019 Jun;62:105-110. doi: 10.1016/j.ejmp.2019.04.015. Epub 2019 May 11.
7. Papaconstadopoulos P, Levesque IR, Aldelaijan S, O'Grady K, **Devic S**, Seuntjens J. Modeling the primary source intensity distribution: reconstruction and inter-comparison of six Varian TrueBeam sources. *Phys Med Biol.* 2019 Jul 2;64(13):135005. doi: 10.1088/1361-6560/ab1ccc.
8. **Devic S**, Bekerat H, Garant A, Vuong T. Optimization of HDRBT boost dose delivery for patients with rectal cancer. *Brachytherapy.* 2019 Jul - Aug;18(4):559-563. doi: 10.1016/j.brachy.2019.02.001. Epub 2019 Mar 23.

#### Marie Duclos

1. Famulari G, **Duclos M**, Enger SA. A novel <sup>169</sup>Yb-based dynamic-shield intensity modulated brachytherapy delivery system for prostate cancer. *Med Phys.* 2019 Dec 12. doi: 10.1002/mp.13959. [Epub ahead of print]
2. Adil K, Popovic M, Cury FL, Faria SL, **Duclos M**, Souhami L. Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. *Pract Radiat Oncol.* 2019 Jan;9(1):24-28. doi: 10.1016/j.prr.2018.07.006. Epub 2018 Aug 7.

#### Michael Evans

1. Serban M, Lambert C, Ruo R, Maietta C, Parker W, **Evans M**, Hijal T. Computed tomography-based virtual simulation versus ultrasound-based clinical setup in electron breast boost radiotherapy: Methodology for CT-based electron virtual simulation. *Phys Med.* 2019 Nov;67:100-106. doi: 10.1016/j.ejmp.2019.10.030. Epub 2019 Nov 6.

#### Marc Fabian

1. Fakim H, **Fabian MR**. Communication Is Key: 5'-3' Interactions that Regulate mRNA Translation and Turnover. *Adv Exp Med Biol.* 2019;1203:149-164. doi: 10.1007/978-3-030-31434-7\_6.
2. Rivera B, Nadaf J, Fahiminiya S, Apellaniz-Ruiz M, Saskin A, Chong AS, Sharma S, Wagener R, Revil T, Condello V, Harra Z, Hamel N, Sabbaghian N, Muchantef K, Thomas C, de Kock L, Hébert-Blouin MN, Bassenden AV, Rabenstein H, Mete O, Paschke R, Pusztaszeri MP, Paulus W, Berghuis A, Ragoussis J, Nikiforov YE, Siebert R, Albrecht S, Turcotte R, Hasselblatt M, **Fabian MR**, Foulkes WD. DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. *J Clin Invest.* 2019 Dec 5. pii: 130206. doi: 10.1172/JCI130206. [Epub ahead of print]



3. **Fabian MR.** Of seeds and supplements: structural insights into extended microRNA-target pairing. *EMBO J.* 2019 Jul 1;38(13):e102477. doi: 10.15252/embj.2019102477. Epub 2019 Jun 18.
4. Apellaniz-Ruiz M, Segni M, Kettwig M, Glüer S, Pelletier D, Nguyen VH, Wagener R, López C, Muchantef K, Bouron-Dal Soglio D, Sabbaghian N, Wu MK, Zannella S, **Fabian MR**, Siebert R, Menke J, Priest JR, Foulkes WD. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. *N Engl J Med.* 2019 May 9;380(19):1834-1842. doi: 10.1056/NEJMoa1812169.
5. Choquet K, Forget D, Meloche E, Dicaire MJ, Bernard G, Vanderver A, Schiffmann R, **Fabian MR**, Teichmann M, Coulombe B, Brais B, Kleinman CL. Leukodystrophy-associated *POLR3A* mutations down-regulate the RNA polymerase III transcript and important regulatory RNA *BC200*. *J Biol Chem.* 2019 May 3;294(18):7445-7459. doi: 10.1074/jbc.RA118.006271. Epub 2019 Mar 21.
6. Duchaine TF, **Fabian MR.** Mechanistic Insights into MicroRNA-Mediated Gene Silencing. *Cold Spring Harb Perspect Biol.* 2019 Mar 1;11(3). pii: a032771. doi: 10.1101/cshperspect.a032771. Review.

### Sergio Faria

1. Chatterjee A, Serban M, **Faria S**, Souhami L, Cury F, Seuntjens J. Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. *Phys Med.* 2020 Jan;69:36-43. doi: 10.1016/j.ejmp.2019.11.023. Epub 2019 Dec 6.
2. Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, **Faria SL**, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. *Radiother Oncol.* 2019 Jun;135:19-24. doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5.
3. Albers J, Parker W, Kildea J, Pembroke C, **Faria S.** Chest wall pain following lung stereotactic body radiation therapy using 48Gy in three fractions: A search for predictors. *Cancer Radiother.* 2019 Apr;23(2):98-103. doi: 10.1016/j.canrad.2018.07.140. Epub 2019 Apr 2.
4. Adil K, Popovic M, Cury FL, **Faria SL**, Duclos M, Souhami L. Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. *Pract Radiat Oncol.* 2019 Jan;9(1):24-28. doi: 10.1016/j.prro.2018.07.006. Epub 2018 Aug 7.

### Cristiano Ferrario

1. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE):

- overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18.
- Ritch E, Fu SYF, Herberts C, Wang G, Warner EW, Schönlaue E, Taavitsainen S, Murtha AJ, Vandekerckhove G, Beja K, Loktionova Y, Khalaf D, Fazli L, Kushnir I, **Ferrario C**, Hotte S, Annala M, Chi KN, Wyatt AW. Identification of Hypermethylation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. *Clin Cancer Res.* 2019 Nov 19. doi: 10.1158/1078-0432.CCR-19-1623. [Epub ahead of print]
  - Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, **Ferrario C**, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalciou C, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res.* 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.
  - Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak M, **Ferrario C**, Basik M. Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. *Clin Cancer Res.* 2019 Dec 1;25(23):7229-7242. doi: 10.1158/1078-0432.CCR-19-1268. Epub 2019 Sep 12.
  - Cavallone L, Aldamry M, Lafleur J, Lan C, Gonzalez Ginestet P, Alirezaie N, **Ferrario C**, Aguilar-Mahecha A, Basik M. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR. *Cancer Epidemiol Biomarkers Prev.* 2019 May;28(5):909-916. doi: 10.1158/1055-9965.EPI-18-0586. Epub 2019 Mar 1.

### Lorenzo Ferri

- Cools-Lartigue J, **Ferri LE**. Routine Esophagram for Detecting Anastomotic Leak After Esophagectomy. *JAMA Surg.* 2019 Dec 11. doi: 10.1001/jamasurg.2019.4931. [Epub ahead of print] No abstract available.
- Cools-Lartigue J, **Ferri L**. Hybrid esophagectomy: the best of both worlds. *J Thorac Dis.* 2019 Sep;11(Suppl 15):S1951-S1953. doi: 10.21037/jtd.2019.08.13. No abstract available.
- Licchetta L, Vignatelli L, Zenesini C, Mostacci B, **Ferri L**, Provini F, Tinuper P, Bisulli F. Sleep-related hypermotor epilepsy: A prediction cohort study on sleep/awake patterns of seizures. *Epilepsia.* 2019 Nov;60(11):e115-e120. doi: 10.1111/epi.16369. Epub 2019 Oct 15.
- Ferri L**. Clinical T4b Esophageal Cancer: Can We Make an "Unresectable" Tumour Resectable? *Ann Surg Oncol.* 2020 Feb;27(2):329-330. doi: 10.1245/s10434-019-07734-9. Epub 2019 Aug 22. No abstract available.
- Trepanier M, Dumitra T, Sorial R, Sibli A, Vassiliou M, Fried GM, Feldman LS, **Ferri LE**, Lee L, Mueller CL. Comparison of Dor and Nissen fundoplication after laparoscopic paraesophageal hernia repair. *Surgery.* 2019 Oct;166(4):540-546. doi: 10.1016/j.surg.2019.06.031. Epub 2019 Aug 13.

6. Gowing SD, Chow SC, Cools-Lartigue JJ, Chen CB, Najmeh S, Goodwin-Wilson M, Jiang HY, Bourdeau F, Beauchamp A, Angers I, Giannias B, Spicer JD, Rousseau S, Qureshi ST, **Ferri LE**. Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis through Host Toll-like Receptor 4 Activation. *J Thorac Oncol*. 2019 Dec;14(12):2097-2108. doi: 10.1016/j.jtho.2019.07.023. Epub 2019 Aug 2.
7. Rayes RF, Mouhanna JG, Nicolau I, Bourdeau F, Giannias B, Rousseau S, Quail D, Walsh L, Sangwan V, Bertos N, Cools-Lartigue J, **Ferri LE**, Spicer JD. Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects. *JCI Insight*. 2019 Jul 25;5. pii: 128008. doi: 10.1172/jci.insight.128008.
8. Evangelisti S, Pittau F, Testa C, Rizzo G, Gramegna LL, **Ferri L**, Coito A, Cortelli P, Calandra-Buonaura G, Bisquoli F, Bianchini C, Manners DN, Talozzi L, Tonon C, Lodi R, Tinuper P. L-Dopa Modulation of Brain Connectivity in Parkinson's Disease Patients: A Pilot EEG-fMRI Study. *Front Neurosci*. 2019 Jun 14;13:611. doi: 10.3389/fnins.2019.00611. eCollection 2019.
9. Sorial RK, Ali M, Kaneva P, Fiore JF Jr, Vassiliou M, Fried GM, Feldman LS, **Ferri LE**, Lee L, Mueller CL. Modern era surgical outcomes of elective and emergency giant paraesophageal hernia repair at a high-volume referral center. *Surg Endosc*. 2020 Jan;34(1):284-289. doi: 10.1007/s00464-019-06764-4. Epub 2019 Mar 28.
10. Alnasser S, Agnihotram R, Martel M, Mayrand S, Franco E, **Ferri L**. Predictors of dysplastic and neoplastic progression of Barrett's esophagus. *Can J Surg*. 2019 Apr 1;62(2):93-99.
11. Mueller CL, Lisbona R, Sorial R, Sibli A, **Ferri LE**. Sentinel Lymph Node Sampling for Early Gastric Cancer-Preliminary Results of A North American Prospective Study. *J Gastrointest Surg*. 2019 Jun;23(6):1113-1121. doi: 10.1007/s11605-018-04098-5. Epub 2019 Mar 11.
12. Bouchard P, Molina JC, Cools-Lartigue J, Spicer J, Mueller CL, **Ferri LE**. Endoscopic Submucosal Dissection for Esophageal Adenocarcinoma: A North American Perspective. *J Gastrointest Surg*. 2019 Jun;23(6):1087-1094. doi: 10.1007/s11605-018-04093-w. Epub 2019 Jan 31.
13. Minnella EM, **Ferri L**, Carli F. Considerations in Prehabilitation for Esophagogastric Cancer Surgery-Reply. *JAMA Surg*. 2019 May 1;154(5):463-464. doi: 10.1001/jamasurg.2018.5593. No abstract available.
14. Cools-Lartigue J, **Ferri L**. Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer? *Ann Surg Oncol*. 2019 Apr;26(4):1014-1027. doi: 10.1245/s10434-019-07162-9. Epub 2019 Jan 23.
15. Renaud S, Seitlinger J, St-Pierre D, Garfinkle R, Al Lawati Y, Guerrera F, Ruffini E, Falcoz PE, Massard G, **Ferri L**, Spicer J. Prognostic value of neutrophil to lymphocyte ratio in lung metastasectomy for colorectal cancer. *Eur J Cardiothorac Surg*. 2019 May 1;55(5):948-955. doi: 10.1093/ejcts/ezy388.
16. Low DE, Allum W, De Manzoni G, **Ferri L**, Immanuel A, Kuppusamy M, Law S, Lindblad M, Maynard N, Neal J, Pramesh CS, Scott M, Mark Smithers B, Addor V, Ljungqvist O. Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations. *World J Surg*. 2019 Feb;43(2):299-330. doi: 10.1007/s00268-018-4786-4. Review.

17. Cools-Lartigue J, **Ferri L**. Radiation Is Not a Solution for Suboptimal Surgery. A Response to the Conclusions Drawn From the Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma With or Without Neoadjuvant Chemoradiotherapy Study. *Ann Surg*. 2019 Jul;270(1):e13-e14. doi: 10.1097/SLA.0000000000003020. No abstract available.
18. Renaud S, Seitlinger J, Lawati YA, Guerrera F, Falcoz PE, Massard G, **Ferri L**, Spicer J. Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations. *Ann Surg*. 2019 Dec;270(6):1170-1177. doi: 10.1097/SLA.0000000000002829.

### William Foulkes

1. **Foulkes W**. Cancer genetics-one family at a time. *Clin Invest Med*. 2019 Dec 29;42(4):E7-E13. doi: 10.25011/cim.v42i4.33344.
2. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, **Foulkes WD**, Antoniou AC, Tischkowitz M. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. *J Clin Oncol*. 2019 Dec 16;JCO1901907. doi: 10.1200/JCO.19.01907. [Epub ahead of print]
3. Rivera B, Nadaf J, Fahiminiya S, Apellaniz-Ruiz M, Saskin A, Chong AS, Sharma S, Wagener R, Revil T, Condello V, Harra Z, Hamel N, Sabbaghian N, Muchantef K, Thomas C, de Kock L, Hébert-Blouin MN, Bassenden AV, Rabenstein H, Mete O, Paschke R, Pusztaszeri MP, Paulus W, Berghuis A, Ragoussis J, Nikiforov YE, Siebert R, Albrecht S, Turcotte R, Hasselblatt M, Fabian MR, **Foulkes WD**. DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. *J Clin Invest*. 2019 Dec 5. pii: 130206. doi: 10.1172/JCI130206. [Epub ahead of print]
4. Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, **Foulkes WD**, Reis-Filho JS. Erratum: Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers.

- NPJ Breast Cancer. 2019 Nov 19;5:44. doi: 10.1038/s41523-019-0140-8. eCollection 2019.
- Bongiovanni M, Sykietis GP, La Rosa S, Bisig B, Trimech M, Missiaglia E, Gremaud M, Salvatori Chappuis V, De Vito C, Sciarra A, **Foulkes WD**, Pusztaszeri M. Macrofollicular Variant of Follicular Thyroid Carcinoma: A Rare Underappreciated Pitfall in the Diagnosis of Thyroid Carcinoma. *Thyroid*. 2020 Jan;30(1):72-80. doi: 10.1089/thy.2018.0607. Epub 2019 Dec 30.
  - Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castela JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, **Foulkes WD**, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Poczta T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowitz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH,

- Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P. The FANCM:p.Arg658\* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer*. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019.
7. Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, Mes-Masson AM, **Foulkes WD**, Rivera B, Tonin PN, Ragoussis J, Dimas AS. Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer. *Front Genet*. 2019 Oct 18;10:1005. doi: 10.3389/fgene.2019.01005. eCollection 2019.
  8. Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, **Foulkes WD**, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers? *Menopause*. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]
  9. Guillerman RP, **Foulkes WD**, Priest JR. Imaging of DICER1 syndrome. *Pediatr Radiol*. 2019 Oct;49(11):1488-1505. doi: 10.1007/s00247-019-04429-x. Epub 2019 Oct 16. Review.
  10. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Jensen TD, Oster PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, **Foulkes WD**, Aprikian A, van Randerad H, Davidson R, Longmuir M, Ruijs MWG, Helder van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcróna K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *Eur Urol*. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.
  11. Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, **Foulkes WD**, Veillette A, Vinh DC. [Loss of human ICOSLG results in combined immunodeficiency]. *Med Sci (Paris)*. 2019 Aug-Sep;35(8-9):625-628. doi: 10.1051/medsci/2019126. Epub 2019 Sep 18. French. No abstract available.

12. Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, **Foulkes WD**, Reis-Filho JS. Homologous recombination DNA repair defects in PALB2-associated breast cancers. *NPJ Breast Cancer*. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019. Erratum in: *NPJ Breast Cancer*. 2019 Nov 19;5:44.
13. Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, **Foulkes WD**, Porco JA Jr, Park M, Pelletier J, Huang S. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. *Mol Cancer Ther*. 2019 Nov;18(11):2158-2170. doi: 10.1158/1535-7163.MCT-19-0162. Epub 2019 Aug 8.
14. Nguyen VH, Bouron-Dal Soglio D, **Foulkes WD**. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. Reply. *N Engl J Med*. 2019 Aug 8;381(6):587. doi: 10.1056/NEJMc1907523. No abstract available.
15. de Kock L, Wu MK, **Foulkes WD**. Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes. *Hum Mutat*. 2019 Nov;40(11):1939-1953. doi: 10.1002/humu.23877. Epub 2019 Aug 17.
16. Cullinan N, Villani A, Mourad S, Somers GR, Reichman L, van Engelen K, Stephens D, Weksberg R, **Foulkes WD**, Malkin D, Grant R, Goudie C. An eHealth decision-support tool to prioritize referral practices for genetic evaluation of patients with Wilms tumor. *Int J Cancer*. 2020 Feb 15;146(4):1010-1017. doi: 10.1002/ijc.32561. Epub 2019 Jul 30.
17. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutranoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, **Foulkes WD**, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, López-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K,

- Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C; KConFab Investigators, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Hum Mutat.* 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818.
18. Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, **Foulkes WD**, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Collaborators GS, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Hum Mutat.* 2019 Oct;40(10):1781-1796. doi: 10.1002/humu.23804. Epub 2019 Jul 3.
19. Apellaniz-Ruiz M, Segni M, Kettwig M, Glüer S, Pelletier D, Nguyen VH, Wagener R, López C, Muchantef K, Bouron-Dal Soglio D, Sabbaghian N, Wu MK, Zannella S, Fabian MR, Siebert R, Menke J, Priest JR, **Foulkes WD**. Mesenchymal Hamartoma of the Liver and DICER1 Syndrome. *N Engl J Med.* 2019 May 9;380(19):1834-1842. doi: 10.1056/NEJMoA1812169.
20. **Foulkes WD**, Witkowski L. Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. *N Engl J Med.* 2019 Apr 11;380(15):e22. doi: 10.1056/NEJMc1817336. No abstract available.
21. de Kock L, Priest JR, **Foulkes WD**, Alexandrescu S. An update on the central nervous system manifestations of DICER1 syndrome. *Acta Neuropathol.* 2019 Apr 5. doi: 10.1007/s00401-019-01997-y. [Epub ahead of print] Review.
22. Pejovic T, McCluggage WG, Krieg AJ, Xu F, Lee DM, Witkowski L, **Foulkes WD**. The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. *Gynecol Oncol Rep.* 2019 Feb 17;28:47-49. doi: 10.1016/j.gore.2019.02.002. eCollection 2019 May.
23. Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, **Foulkes WD**, Witcher M. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. *Cancer Res.* 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.
24. Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, **Foulkes WD**, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Oophorectomy and risk of contralateral breast cancer among



- BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.
25. Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, Ten Broeke SW, de Miranda NFCC, Kuiper RA, Kamping EJ, Jansen EAM, Vink-Börger ME, Popp I, Lang A, Spier I, Hüneburg R, James PA, Li N, Staninova M, Lindsay H, Cockburn D, Spasic-Boskovic O, Clendenning M, Sweet K, Capellá G, Sjursen W, Høberg-Vetti H, Jongmans MC, Neveling K, Geurts van Kessel A, Morreau H, Hes FJ, Sijmons RH, Schackert HK, Ruiz-Ponte C, Dymerska D, Lubinski J, Rivera B, **Foulkes WD**, Tomlinson IP, Valle L, Buchanan DD, Kenwrick S, Adlard J, Dimovski AJ, Campbell IG, Aretz S, Schindler D, van Wezel T, Hoogerbrugge N, Kuiper RP. Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. *Cancer Cell.* 2019 Feb 11;35(2):256-266.e5. doi: 10.1016/j.ccell.2018.12.011.
26. Gallon R, Mühlegger B, Wenzel SS, Sheth H, Hayes C, Aretz S, Dahan K, **Foulkes W**, Kratz CP, Ripperger T, Azizi AA, Baris Feldman H, Chong AL, Demirsoy U, Florkin B, Imschweiler T, Januszkiewicz-Lewandowska D, Lobitz S, Nathrath M, Pander HJ, Perez-Alonso V, Perne C, Ragab I, Rosenbaum T, Rueda D, Seidel MG, Suerink M, Taeubner J, Zimmermann SY, Zschocke J, Borthwick GM, Burn J, Jackson MS, Santibanez-Koref M, Wimmer K. A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. *Hum Mutat.* 2019 May;40(5):649-655. doi: 10.1002/humu.23721. Epub 2019 Mar 6.
27. Metcalfe K, Lynch HT, **Foulkes WD**, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. *Br J Cancer.* 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.
28. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, **Foulkes WD**, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun.* 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
29. Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez AV, Guiot MC, Lockwood WW, Spicer JD, Agaimy A, Pastor WA, Dostie J, Rak J, **Foulkes WD**, Huang S. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. *Nat Commun.* 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
30. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, **Foulkes WD**, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the

- Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. *J Clin Oncol.* 2019 Feb 20;37(6):461-470. doi: 10.1200/JCO.18.00474. Epub 2019 Jan 4.
31. de Kock L, Hillmer M, Wagener R, Soglio DB, Sabbaghian N, Siebert R, Priest JR, Miller M, **Foulkes WD**. Further evidence that full gene deletions of DICER1 predispose to DICER1 syndrome. *Genes Chromosomes Cancer.* 2019 Aug;58(8):602-604. doi: 10.1002/gcc.22728. Epub 2019 Jan 28. No abstract available.
  32. Gayden T, Sepulveda FE, Khuong-Quang DA, Pratt J, Valera ET, Garrigue A, Kelso S, Sicheri F, Mikael LG, Hamel N, Bajic A, Dali R, Deshmukh S, Dervovic D, Schramek D, Guerin F, Taipale M, Nikbakht H, Majewski J, Moshous D, Charlebois J, Abish S, Bole-Feysot C, Nitschke P, Bader-Meunier B, Mitchell D, Thieblemont C, Battistella M, Gravel S, Nguyen VH, Conyers R, Diana JS, McCormack C, Prince HM, Besnard M, Blanche S, Ekert PG, Fraitag S, **Foulkes WD**, Fischer A, Neven B, Michonneau D, de Saint Basile G, Jabado N. Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. *Nat Genet.* 2019 Jan;51(1):196. doi: 10.1038/s41588-018-0304-8.
  33. Castellsagué E, Li R, Aligue R, González S, Sanz J, Martin E, Velasco À, Capellá G, Stewart CJR, Vidal A, Majewski J, Rivera B, Polak P, Matias-Guiu X, Brunet J, **Foulkes WD**. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. *Hum Mutat.* 2019 Jan;40(1):36-41. doi: 10.1002/humu.23676. Epub 2018 Nov 20.
  34. McCluggage WG, Chong AS, Attygalle AD, Clarke BA, Chapman W, Rivera B, **Foulkes WD**. Expanding the morphological spectrum of ovarian microcystic stromal tumour. *Histopathology.* 2019 Feb;74(3):443-451. doi: 10.1111/his.13755. Epub 2018 Dec 5.
  35. Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, **Foulkes WD**. Ovarian small cell carcinoma in one of a pair of monozygous twins. *Fam Cancer.* 2019 Apr;18(2):161-163. doi: 10.1007/s10689-018-0108-0.
  36. van der Tuin K, de Kock L, Kamping EJ, Hannema SE, Pouwels MM, Niedziela M, van Wezel T, Hes FJ, Jongmans MC, **Foulkes WD**, Morreau H. Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome. *J Clin Endocrinol Metab.* 2019 Feb 1;104(2):277-284. doi: 10.1210/jc.2018-00774.

### **Eduardo Franco**

1. Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, **Franco EL**, Moscicki AB, Mahmud SM, Wheeler CM, Rivera-Paredes B, Hernández-López R, León-Maldonado L, Salmerón J; FRIDA Study Group. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. *JAMA Netw Open.* 2019 Nov 1;2(11):e1915781. doi: 10.1001/jamanetworkopen.2019.15781.
2. Malagón T, Louvanto K, Ramanakumar AV, Koushik A, Coutlée F, **Franco EL**; Biomarkers of Cervical Cancer Risk Study Team. Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age. *Gynecol Oncol.* 2019 Nov;155(2):245-253. doi: 10.1016/j.ygyno.2019.09.010. Epub 2019 Oct 8.

3. Widdice LE, Bernstein DI, **Franco EL**, Ding L, Brown DR, Ermel AC, Higgins L, Kahn JA. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. *Vaccine*. 2019 Oct 23;37(45):6832-6841. doi: 10.1016/j.vaccine.2019.08.052. Epub 2019 Sep 30.
4. Sorin M, **Franco EL**, Quesnel-Vallée A. Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program. *Curr Oncol*. 2019 Aug;26(4):266-269. doi: 10.3747/co.26.4867. Epub 2019 Aug 1. No abstract available.
5. Wissing MD, Burchell AN, El-Zein M, Tellier PP, Coutlée F, **Franco EL**. Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2019 Nov;28(11):1825-1834. doi: 10.1158/1055-9965.EPI-19-0618. Epub 2019 Sep 5.
6. Vorsters A, Bonanni P, Maltezou HC, Yarwood J, Brewer NT, Bosch FX, Hanley S, Cameron R, **Franco EL**, Arbyn M, Muñoz N, Kojouharova M, Pattyn J, Baay M, Karafillakis E, Van Damme P. The role of healthcare providers in HPV vaccination programs - A meeting report. *Papillomavirus Res*. 2019 Dec;8:100183. doi: 10.1016/j.pvr.2019.100183. Epub 2019 Aug 30.
7. El-Zein M, Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, Colares de Borba P, Teixeira JC, Moscicki AB, Harper DM, Tying SK, Ramjattan B, Dubin G, **Franco EL**; HPV-007 Study Group. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. *Sex Transm Dis*. 2019 Oct;46(10):663-669. doi: 10.1097/OLQ.0000000000001053.
8. Coldman AJ, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan DJ, Lee M, Elwood-Martin R, Gentile L, Peacock S, Stuart GCE, **Franco EL**, Ogilvie GS. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. *Int J Cancer*. 2019 Jun 27. doi: 10.1002/ijc.32524. [Epub ahead of print]
9. Volesky KD, El-Zein M, **Franco EL**, Brenner DR, Friedenreich CM, Ruan Y; ComPARE Study Team. Corrigendum to "Estimates of the future burden of cancer attributable to infections in Canada" [*Prev. Med.* 122 (2019) 118-127]. *Prev Med*. 2019 Dec;129:105731. doi: 10.1016/j.ypmed.2019.05.019. Epub 2019 May 29. No abstract available.
10. Volesky KD, El-Zein M, **Franco EL**, Brenner DR, Friedenreich CM, Ruan Y; ComPARE Study Team. Corrigendum to "Cancers attributable to infections in Canada" [*Prev. Med.* 122 (2019) 109-117]. *Prev Med*. 2019 Dec;129:105730. doi: 10.1016/j.ypmed.2019.05.018. Epub 2019 May 29. No abstract available.
11. Brenner DR, Friedenreich CM, Ruan Y, Poirier AE, Walter SD, King WD, **Franco EL**, Demers PA, Villeneuve PJ, Grevers X, Nuttall R, Smith LM, Volesky KD, O'Sullivan DE, De P; ComPARE Study Team. The burden of cancer attributable to modifiable risk factors in Canada: Methods overview. *Prev Med*. 2019 May;122:3-8. doi: 10.1016/j.ypmed.2019.03.007.
12. Volesky KD, El-Zein M, **Franco EL**, Brenner DR, Friedenreich CM, Ruan Y; ComPARE Study Team. Estimates of the future burden of cancer attributable to infections in Canada. *Prev Med*. 2019 May;122:118-127. doi: 10.1016/j.ypmed.2019.04.006. Erratum in: *Prev Med*. 2019 Dec;129:105731.

13. Volesky KD, El-Zein M, **Franco EL**, Brenner DR, Friedenreich CM, Ruan Y; ComPARE Study Team. Cancers attributable to infections in Canada. *Prev Med.* 2019 May;122:109-117. doi: 10.1016/j.ypmed.2019.03.035. Erratum in: *Prev Med.* 2019 Dec;129:105730.
14. Wissing MD, Louvanto K, Comète E, Burchell AN, El-Zein M, Rodrigues A, Tellier PP, Coutlée F, **Franco EL**. Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples. *J Infect Dis.* 2019 Aug 30;220(7):1152-1161. doi: 10.1093/infdis/jiz238.
15. El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb WH, Hemmings R, Behr MA, **Franco EL**; CASSIS Study Group\*. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. *Cancer Epidemiol Biomarkers Prev.* 2019 Jul;28(7):1134-1140. doi: 10.1158/1055-9965.EPI-18-1338. Epub 2019 Apr 23.
16. ThekkePurakkal AS, Nicolau B, Burk RD, **Franco EL**, Schlecht NF. Genetic variants in CYP and GST genes, smoking and risk for head and neck cancers: a gene-environment interaction hospital-based case-control study among Canadian Caucasians. *Carcinogenesis.* 2019 Apr 2. pii: bgz051. doi: 10.1093/carcin/bgz051. [Epub ahead of print]
17. Shapiro SB, **Franco EL**. Restoring Dignity in Academic Publishing Is a Collective Duty. *JDR Clin Trans Res.* 2019 Jan;4(1):5-8. doi: 10.1177/2380084418806839. Epub 2018 Oct 8. No abstract available.
18. Sichoero L, El-Zein M, Ferreira S, **Franco EL**, Villa LL; Ludwig-McGill Cohort Study. Lack of Association between Human Papillomavirus Types 6 and 11 Genetic Variants and Cervical Abnormalities: The Ludwig-McGill Cohort Study. *Cancer Epidemiol Biomarkers Prev.* 2019 Jun;28(6):1086-1088. doi: 10.1158/1055-9965.EPI-19-0114. Epub 2019 Mar 13.
19. Wissing MD, Greenwald ZR, **Franco EL**. Improving the reporting of cancer-specific mortality and survival in research using cancer registry data. *Cancer Epidemiol.* 2019 Apr;59:232-235. doi: 10.1016/j.canep.2019.02.004. Epub 2019 Mar 2.
20. Poirier AE, Ruan Y, Walter SD, **Franco EL**, Villeneuve PJ, King WD, Volesky KD, O'Sullivan DE, Friedenreich CM, Brenner DR; ComPARE Study Team. The future burden of cancer in Canada: Long-term cancer incidence projections 2013-2042. *Cancer Epidemiol.* 2019 Apr;59:199-207. doi: 10.1016/j.canep.2019.02.011. Epub 2019 Mar 1.
21. Malagón T, Louvanto K, Wissing M, Burchell AN, Tellier PP, El-Zein M, Coutlée F, **Franco EL**. Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. *Lancet Infect Dis.* 2019 Mar;19(3):317-326. doi: 10.1016/S1473-3099(18)30655-8. Epub 2019 Feb 10.
22. Malagón T, Kulasingam S, **Franco EL**. Limitations of simulation models for cervical cancer screening - Authors' reply. *Lancet Oncol.* 2019 Feb;20(2):e69. doi: 10.1016/S1470-2045(19)30012-9. No abstract available.
23. Spinner C, Ding L, Bernstein DI, Brown DR, **Franco EL**, Covert C, Kahn JA. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. *Pediatrics.* 2019 Feb;143(2). pii: e20181902. doi: 10.1542/peds.2018-1902. Epub 2019 Jan 22.
24. El-Zein M, Coutlée F, Tellier PP, Roger M, **Franco EL**, Burchell AN; HITCH Study Group. Human Papillomavirus Infection and Transmission Among Couples Through

- Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals. *JMIR Res Protoc*. 2019 Jan 16;8(1):e11284. doi: 10.2196/11284.
25. Covert C, Ding L, Brown D, **Franco EL**, Bernstein DI, Kahn JA. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. *Hum Vaccin Immunother*. 2019;15(7-8):1962-1969. doi: 10.1080/21645515.2018.1564438. Epub 2019 Feb 20.
  26. Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, Hier M, Rousseau MC, **Franco EL**, Nicolau B. Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study. *Head Neck*. 2019 Mar;41(3):678-685. doi: 10.1002/hed.25436. Epub 2019 Jan 3.
  27. Isidean SD, Wang Y, Mayrand MH, Ratnam S, Coutlée F, **Franco EL**, Abrahamowicz M; CCCaST Study Group. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. *Int J Cancer*. 2019 May 15;144(10):2408-2418. doi: 10.1002/ijc.31970. Epub 2019 Jan 21.
  28. Magnan S, Tota JE, El-Zein M, Burchell AN, Schiller JT, Ferenczy A, Tellier PP, Coutlée F, **Franco EL**; CATCH Study Group. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. *Clin Microbiol Infect*. 2019 Feb;25(2):210-216. doi: 10.1016/j.cmi.2018.04.012. Epub 2018 Apr 21.

#### **Carolyn Freeman**

1. Hijal T, **Freeman CR**, Seuntjens J. Proton beam therapy should remain in the public domain. *CMAJ*. 2019 Nov 18;191(46):E1284. doi: 10.1503/cmaj.73445. No abstract available.
2. Boulet J, Peña J, Hulten EA, Neilan TG, Dragomir A, **Freeman C**, Lambert C, Hijal T, Nadeau L, Brophy JM, Mousavi N. Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck. *J Am Heart Assoc*. 2019 Jul 2;8(13):e005996. doi: 10.1161/JAHA.117.005996. Epub 2019 Jun 19.

#### **Vincent Giguère**

1. Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, **Giguère V**, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. *Nat Commun*. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.
2. Xia H, Dufour CR, **Giguère V**. ERR $\alpha$  as a Bridge Between Transcription and Function: Role in Liver Metabolism and Disease. *Front Endocrinol (Lausanne)*. 2019 Apr 5;10:206. doi: 10.3389/fendo.2019.00206. eCollection 2019. Review.
3. Ghanbari F, Hebert-Losier A, Barry J, Poirier D, **Giguere V**, Mader S, Philip A. Isolation and functional characterization of a novel endogenous inverse agonist of estrogen related receptors (ERRs) from human pregnancy urine. *J Steroid Biochem Mol Biol*. 2019 Jul;191:105352. doi: 10.1016/j.jsbmb.2019.04.001. Epub 2019 Apr 5.

4. Morita M, Siddiqui N, Katsumura S, Rouya C, Larsson O, Nagashima T, Hekmatnejad B, Takahashi A, Kiyonari H, Zang M, St-Arnaud R, Oike Y, **Giguère V**, Topisirovic I, Okada-Hatakeyama M, Yamamoto T, Sonenberg N. Hepatic posttranscriptional network comprised of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. *Proc Natl Acad Sci U S A*. 2019 Apr 16;116(16):7973-7981. doi: 10.1073/pnas.1816023116. Epub 2019 Mar 29.
5. Likhite N, Yadav V, Milliman EJ, Sopariwala DH, Lorca S, Narayana NP, Sheth M, Reineke EL, **Giguère V**, Narkar V. Loss of Estrogen-Related Receptor Alpha Facilitates Angiogenesis in Endothelial Cells. *Mol Cell Biol*. 2019 Feb 15;39(5). pii: e00411-18. doi: 10.1128/MCB.00411-18. Print 2019 Mar 1.

### Lucy Gilbert

1. Grundy A, Ho V, Abrahamowicz M, Parent MÉ, Siemiatycki J, Arseneau J, **Gilbert L**, Gotlieb WH, Provencher DM, Koushik A. Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: A case-control study. *Int J Cancer*. 2019 Jun 14. doi: 10.1002/ijc.32513. [Epub ahead of print]
2. Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, **Gilbert L**, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. *J Clin Oncol*. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7.
3. El-Zein M, Bouten S, Louvanto K, **Gilbert L**, Gotlieb WH, Hemmings R, Behr MA, Franco EL; CASSIS Study Group\*. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. *Cancer Epidemiol Biomarkers Prev*. 2019 Jul;28(7):1134-1140. doi: 10.1158/1055-9965.EPI-18-1338. Epub 2019 Apr 23.
4. Leung L, Grundy A, Siemiatycki J, Arseneau J, **Gilbert L**, Gotlieb WH, Provencher DM, Aronson KJ, Koushik A. Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk. *Cancer Epidemiol Biomarkers Prev*. 2019 May;28(5):987-995. doi: 10.1158/1055-9965.EPI-18-1112. Epub 2019 Mar 6.
5. Albeesh R, Turgeon GA, Alfieri J, Mansure JJ, Fu L, Arseneau J, Zeng X, Jardon K, **Gilbert L**, Souhami L. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. *Gynecol Oncol*. 2019 Jan;152(1):26-30. doi: 10.1016/j.ygyno.2018.11.002. Epub 2018 Nov 22.
6. Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, **Gilbert L**, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. *Clin Cancer Res*. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

### Walter Gotlieb

1. Oceau D, Abitbol J, Amajoud Z, Laskov I, Ferenczy A, Pelmus M, Eisenberg N, Kessous R, Matanes E, Lau S, Yasmeen A, Lopez-Ozuna V, Salvador S, **Gotlieb WH**, Kogan L. Targeted sequencing of histologically defined serous endometrial cancer

- reflects prognosis and correlates with preoperative biopsy. *Gynecol Oncol Rep.* 2019 Nov 27;30:100521. doi: 10.1016/j.gore.2019.100521. eCollection 2019 Nov.
2. Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, **Gotlieb W**, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. *Gynecol Oncol.* 2019 Nov 18. pii: S0090-8258(19)31670-1. doi: 10.1016/j.ygyno.2019.11.019. [Epub ahead of print]
  3. Abitbol J, **Gotlieb W**, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. *Int J Gynecol Cancer.* 2019 Nov;29(9):1341-1347. doi: 10.1136/ijgc-2019-000413. Epub 2019 Oct 9.
  4. Oceau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, Greenwood CMT, Van Kempen LC, Salvador S, Lau S, Tonin PN, Yasmeen A, **Gotlieb WH**. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. *Mol Cancer Res.* 2019 Dec;17(12):2422-2431. doi: 10.1158/1541-7786.MCR-19-0398. Epub 2019 Sep 17.
  5. Wissing M, Mitric C, Amajoud Z, Abitbol J, Yasmeen A, López-Ozuna V, How J, Kessous R, Eisenberg N, Lau S, Salvador S, **Gotlieb WH**, Kogan L. Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. *Gynecol Oncol.* 2019 Oct;155(1):27-33. doi: 10.1016/j.ygyno.2019.07.016. Epub 2019 Jul 24.
  6. Kessous R, How J, Abitbol J, Puzhakkal S, Kogan L, Yasmeen A, Salvador S, **Gotlieb WH**, Lau S. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment. *Int J Gynecol Cancer.* 2019 Sep;29(7):1121-1125. doi: 10.1136/ijgc-2019-000387. Epub 2019 Jul 17.
  7. Grundy A, Ho V, Abrahamowicz M, Parent MÉ, Siemiatycki J, Arseneau J, Gilbert L, **Gotlieb WH**, Provencher DM, Koushik A. Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: A case-control study. *Int J Cancer.* 2019 Jun 14. doi: 10.1002/ijc.32513. [Epub ahead of print]
  8. Nguyen DB, Czuzoj-Shulman N, Alshaya A, **Gotlieb WH**, Abenhaim HA. The effect of rural vs. urban setting on the management and outcomes of surgery for endometrial cancer. *J Gynecol Obstet Hum Reprod.* 2019 Nov;48(9):745-749. doi: 10.1016/j.jogoh.2019.06.001. Epub 2019 Jun 5.
  9. El-Zein M, Bouten S, Louvanto K, Gilbert L, **Gotlieb WH**, Hemmings R, Behr MA, Franco EL; CASSIS Study Group\*. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. *Cancer Epidemiol Biomarkers Prev.* 2019 Jul;28(7):1134-1140. doi: 10.1158/1055-9965.EPI-18-1338. Epub 2019 Apr 23.
  10. Matanes E, **Gotlieb WH**. Immunotherapy of gynecological cancers. *Best Pract Res Clin Obstet Gynaecol.* 2019 Oct;60:97-110. doi: 10.1016/j.bpobgyn.2019.03.005. Epub 2019 Mar 21. Review.
  11. Leung L, Grundy A, Siemiatycki J, Arseneau J, Gilbert L, **Gotlieb WH**, Provencher DM, Aronson KJ, Koushik A. Shift Work Patterns, Chronotype, and Epithelial Ovarian

- Cancer Risk. *Cancer Epidemiol Biomarkers Prev.* 2019 May;28(5):987-995. doi: 10.1158/1055-9965.EPI-18-1112. Epub 2019 Mar 6.
12. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, **Gotlieb WH**, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun.* 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
  13. Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M, Rosberger Z, Geva N, **Gotlieb WH**, Mintz A. Gender differences in how physicians access and process information. *Gynecol Oncol Rep.* 2019 Jan 2;27:50-53. doi: 10.1016/j.gore.2018.12.008. eCollection 2019 Feb. Review.
  14. Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, **Gotlieb WH**. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. *BMC Cancer.* 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4.
  15. Matanes E, Abitbol J, Kessous R, Kogan L, Oceau D, Lau S, Salvador S, **Gotlieb WH**. Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer. *J Obstet Gynaecol Can.* 2019 Apr;41(4):450-458. doi: 10.1016/j.jogc.2018.09.013. Epub 2018 Dec 7.
  16. Piedimonte S, Czuzoj-Shulman N, **Gotlieb W**, Abenhaim HA. Robotic Radical Hysterectomy for Cervical Cancer: A Population-Based Study of Adoption and Immediate Postoperative Outcomes in the United States. *J Minim Invasive Gynecol.* 2019 Mar - Apr;26(3):551-557. doi: 10.1016/j.jmig.2018.08.012. Epub 2018 Sep 5.

### Celia Greenwood

1. Tounkara F, Lefebvre G, **Greenwood C**, Oualkacha K. A flexible copula-based approach for the analysis of secondary phenotypes in ascertained samples. *Stat Med.* 2019 Dec 23. doi: 10.1002/sim.8416. [Epub ahead of print]
2. Jeyakumar T, Fodil N, Van Der Kraak L, Meunier C, Cayrol R, McGregor K, Langlais D, **Greenwood CMT**, Beauchemin N, Gros P. Inactivation of Interferon Regulatory Factor 1 Causes Susceptibility to Colitis-Associated Colorectal Cancer. *Sci Rep.* 2019 Dec 11;9(1):18897. doi: 10.1038/s41598-019-55378-2.
3. McGregor K, Labbe A, **Greenwood CMT**. MDiNE: A model to estimate differential co-occurrence networks in microbiome studies. *Bioinformatics.* 2019 Nov 7. pii: btz824. doi: 10.1093/bioinformatics/btz824. [Epub ahead of print]
4. Lu T, Klein KO, Colmegna I, Lora M, **Greenwood CMT**, Hudson M. Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis. *BMC Med Genomics.* 2019 Oct 24;12(1):144. doi: 10.1186/s12920-019-0602-8.
5. Ng KP, Richard-Devantoy S, Bertrand JA, Jiang L, Pascoal TA, Mathotaarachchi S, Therriault J, Yatawara C, Kandiah N, **Greenwood CMT**, Rosa-Neto P, Gauthier S; Dominantly Inherited Alzheimer Network. Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. *Int J Geriatr Psychiatry.* 2020 Jan;35(1):60-68. doi: 10.1002/gps.5215. Epub 2019 Oct 22.



6. Oceau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, **Greenwood CMT**, Van Kempen LC, Salvador S, Lau S, Tonin PN, Yasmeen A, Gotlieb WH. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. *Mol Cancer Res*. 2019 Dec;17(12):2422-2431. doi: 10.1158/1541-7786.MCR-19-0398. Epub 2019 Sep 17.
7. Wong C, Chen F, Alirezaie N, Wang Y, Cuggia A, Borgida A, Holter S, Lenko T, Domecq C; Alzheimer's Disease Neuroimaging Initiative, Petersen GM, Syngal S, Brand R, Rustgi AK, Cote ML, Stoffel E, Olson SH, Roberts NJ, Akbari MR, Majewski J, Klein AP, **Greenwood CMT**, Gallinger S, Zogopoulos G. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. *PLoS Genet*. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.
8. Shao X, Hudson M, Colmegna I, **Greenwood CMT**, Fritzler MJ, Awadalla P, Pastinen T, Bernatsky S. Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. *Clin Epigenetics*. 2019 Jul 31;11(1):110. doi: 10.1186/s13148-019-0699-9.
9. Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, **Greenwood CMT**, Basik M, Muanza TM. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. *Sci Rep*. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.
10. Sallis H, Szekely E, Neumann A, Jolicoeur-Martineau A, van IJzendoorn M, Hillegers M, **Greenwood CMT**, Meaney MJ, Steiner M, Tiemeier H, Wazana A, Pearson RM, Evans J. General psychopathology, internalising and externalising in children and functional outcomes in late adolescence. *J Child Psychol Psychiatry*. 2019 Nov;60(11):1183-1190. doi: 10.1111/jcpp.13067. Epub 2019 May 2.
11. Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JB, **Greenwood CMT**; Alzheimer's Disease Neuroimaging Initiative. Constrained instruments and their application to Mendelian randomization with pleiotropy. *Genet Epidemiol*. 2019 Jun;43(4):373-401. doi: 10.1002/gepi.22184. Epub 2019 Jan 12.
12. Shokoohi F, Stephens DA, Bourque G, Pastinen T, **Greenwood CMT**, Labbe A. A hidden markov model for identifying differentially methylated sites in bisulfite sequencing data. *Biometrics*. 2019 Mar;75(1):210-221. doi: 10.1111/biom.12965. Epub 2018 Oct 9.
13. Jolicoeur-Martineau A, Wazana A, Szekely E, Steiner M, Fleming AS, Kennedy JL, Meaney MJ, **Greenwood CMT**. Alternating optimization for  $G \times E$  modelling with weighted genetic and environmental scores: Examples from the MAVAN study. *Psychol Methods*. 2019 Apr;24(2):196-216. doi: 10.1037/met0000175. Epub 2018 Aug 13.

### Melissa Henry

1. Wu Y, Levis B, Sun Y, Krishnan A, He C, Riehm KE, Rice DB, Azar M, Yan XW, Neupane D, Bhandari PM, Imran M, Chiovitti MJ, Saadat N, Boruff JT, Cuijpers P, Gilbody S, McMillan D, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, **Henry M**, Ismail Z, Loiselle CG, Mitchell ND, Tonelli M, Al-Adawi S, Beraldi A, Braeken APBM, Büel-Drabe N, Bunevicius A, Carter G, Chen CK, Cheung G, Clover K, Conroy RM, Cukor D, da Rocha E Silva CE, Dabscheck E, Daray FM, Douven E,

Downing MG, Feinstein A, Ferentinos PP, Fischer FH, Flint AJ, Fujimori M, Gallagher P, Gandy M, Goebel S, Grassi L, Härter M, Jenewein J, Jetté N, Julião M, Kim JM, Kim SW, Kjærgaard M, Köhler S, Loosman WL, Löwe B, Martin-Santos R, Massardo L, Matsuoka Y, Mehnert A, Michopoulos I, Misery L, Navines R, O'Donnell ML, Öztürk A, Peceliuniene J, Pintor L, Ponsford JL, Quinn TJ, Reme SE, Reuter K, Rooney AG, Sánchez-González R, Schwarzbald ML, Senturk Cankorur V, Shaaban J, Sharpe L, Sharpe M, Simard S, Singer S, Stafford L, Stone J, Sultan S, Teixeira AL, Tiringier I, Turner A, Walker J, Walterfang M, Wang LJ, White J, Wong DK, Benedetti A, Thombs BD. Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale - Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. *J Psychosom Res.* 2020 Feb;129:109892. doi: 10.1016/j.jpsychores.2019.109892. Epub 2019 Dec 13.

2. **Henry M**, Fuehrmann F, Hier M, Zeitouni A, Kost K, Richardson K, Mlynarek A, Black M, MacDonald C, Chartier G, Zhang X, Rosberger Z, Frenkiel S. Contextual and historical factors for increased levels of anxiety and depression in patients with head and neck cancer: A prospective longitudinal study. *Head Neck.* 2019 Aug;41(8):2538-2548. doi: 10.1002/hed.25725. Epub 2019 Mar 19.
3. Rodriguez AM, Frenkiel S, Desroches J, De Simone A, Chiocchio F, MacDonald C, Black M, Zeitouni A, Hier M, Kost K, Mlynarek A, Bolster-Foucault C, Rosberger Z, **Henry M**. Development and validation of the **McGill** body image concerns scale for use in head and neck oncology (MBIS-HNC): A mixed-methods approach. *Psychooncology.* 2019 Jan;28(1):116-121. doi: 10.1002/pon.4918. Epub 2018 Nov 12.
4. **Henry M**, Alias A, Frenkiel S, Richardson K, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Chartier G, Rosberger Z. Contribution of psychiatric diagnoses to extent of opioid prescription in the first year post-head and neck cancer diagnosis: A longitudinal study. *Psychooncology.* 2019 Jan;28(1):107-115. doi: 10.1002/pon.4917. Epub 2018 Nov 5.

### Michael Hier

1. Krasner JR, Alyouha N, Pusztaszeri M, Forest VI, **Hier MP**, Avior G, Payne RJ. Molecular mutations as a possible factor for determining extent of thyroid surgery. *J Otolaryngol Head Neck Surg.* 2019 Oct 17;48(1):51. doi: 10.1186/s40463-019-0372-5.
2. Mascarella MA, Milad D, Richardson K, Mlynarek A, Payne RJ, Forest VI, **Hier M**, Sadeghi N, Mayo N. Preoperative Risk Index Among Patients Undergoing Thyroid or Parathyroid Surgery. *JAMA Otolaryngol Head Neck Surg.* 2019 Sep 5. doi: 10.1001/jamaoto.2019.2413. [Epub ahead of print]
3. You E, Mascarella MA, Al Jassim A, Forest VI, **Hier MP**, Tamilia M, Pusztaszeri M, Payne RJ. Prevalence and aggressiveness of papillary thyroid carcinoma in surgically-treated graves' disease patients: a retrospective matched cohort study. *J Otolaryngol Head Neck Surg.* 2019 Aug 28;48(1):40. doi: 10.1186/s40463-019-0364-5.
4. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, **Hier M**, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winkquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Eapen L, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Radiotherapy versus transoral robotic surgery and

- neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. *Lancet Oncol.* 2019 Oct;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3. Epub 2019 Aug 12. Erratum in: *Lancet Oncol.* 2019 Dec;20(12):e663.
5. Mascarella MA, Azzi JL, da Silva SD, Mlynarek A, Forest VI, **Hier M**, Richardson K, Sadeghi N. Postoperative infection predicts poor survival in locoregionally advanced oral cancer. *Head Neck.* 2019 Oct;41(10):3624-3630. doi: 10.1002/hed.25885. Epub 2019 Aug 5.
  6. Henry M, Fuehrmann F, **Hier M**, Zeitouni A, Kost K, Richardson K, Mlynarek A, Black M, MacDonald C, Chartier G, Zhang X, Rosberger Z, Frenkiel S. Contextual and historical factors for increased levels of anxiety and depression in patients with head and neck cancer: A prospective longitudinal study. *Head Neck.* 2019 Aug;41(8):2538-2548. doi: 10.1002/hed.25725. Epub 2019 Mar 19.
  7. Mascarella MA, Richardson K, Mlynarek A, Forest VI, **Hier M**, Sadeghi N, Mayo N. Evaluation of a Preoperative Adverse Event Risk Index for Patients Undergoing Head and Neck Cancer Surgery. *JAMA Otolaryngol Head Neck Surg.* 2019 Apr 1;145(4):345-351. doi: 10.1001/jamaoto.2018.4513.
  8. Laprise C, Madathil SA, Schlecht NF, Castonguay G, Soulières D, Nguyen-Tan PF, Allison P, Coutlée F, **Hier M**, Rousseau MC, Franco EL, Nicolau B. Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study. *Head Neck.* 2019 Mar;41(3):678-685. doi: 10.1002/hed.25436. Epub 2019 Jan 3.
  9. Rodriguez AM, Frenkiel S, Desroches J, De Simone A, Chiocchio F, MacDonald C, Black M, Zeitouni A, **Hier M**, Kost K, Mlynarek A, Bolster-Foucault C, Rosberger Z, Henry M. Development and validation of the McGill body image concerns scale for use in head and neck oncology (MBIS-HNC): A mixed-methods approach. *Psychooncology.* 2019 Jan;28(1):116-121. doi: 10.1002/pon.4918. Epub 2018 Nov 12.
  10. Henry M, Alias A, Frenkiel S, Richardson K, **Hier M**, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Chartier G, Rosberger Z. Contribution of psychiatric diagnoses to extent of opioid prescription in the first year post-head and neck cancer diagnosis: A longitudinal study. *Psychooncology.* 2019 Jan;28(1):107-115. doi: 10.1002/pon.4917. Epub 2018 Nov 5.

### Vera Hirsh

1. Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, **Hirsh V**, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC. *J Thorac Oncol.* 2019 Oct 16. pii: S1556-0864(19)33563-4. doi: 10.1016/j.jtho.2019.10.005. [Epub ahead of print]
2. Schuler M, Paz-Ares L, Sequist LV, **Hirsh V**, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. *Lung Cancer.* 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.

3. Melosky B, Juergens R, **Hirsh V**, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. *Oncologist*. 2020 Jan;25(1):64-77. doi: 10.1634/theoncologist.2019-0027. Epub 2019 May 28.
4. Park K, Bennouna J, Boyer M, Hida T, **Hirsh V**, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. *Lung Cancer*. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.
5. Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, **Hirsh V**, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. *Curr Oncol*. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.
6. Cheema PK, Rothenstein J, Melosky B, Brade A, **Hirsh V**. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. *Curr Oncol*. 2019 Feb;26(1):37-42. doi: 10.3747/co.25.4096. Epub 2019 Feb 1. Review.
7. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, **Hirsh V**, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. *J Cancer Res Clin Oncol*. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.
8. Buttiglierio C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, **Hirsh V**, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. *Oncologist*. 2019 Jun;24(6):e251-e259. doi: 10.1634/theoncologist.2018-0089. Epub 2018 Aug 23.

### **Kris Jardon**

1. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, **Jardon K**, Redondo A, Moore RG, Vulsteke C, O'Ceirbhail RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
2. Albeesh R, Turgeon GA, Alfieri J, Mansure JJ, Fu L, Arseneau J, Zeng X, **Jardon K**, Gilbert L, Souhami L. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. *Gynecol Oncol*. 2019 Jan;152(1):26-30. doi: 10.1016/j.ygyno.2018.11.002. Epub 2018 Nov 22.

### Nathalie Johnson

1. Clark G, **Johnson NA**, Saluja SS, Correa JA, Delaney JS. Do Mountain Bikers Know When They Have Had a Concussion and, Do They Know to Stop Riding? *Clin J Sport Med.* 2019 Dec 31. doi: 10.1097/JSM.0000000000000819. [Epub ahead of print]
2. Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, **Johnson NA**, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. *Nat Commun.* 2019 Oct 17;10(1):4712. doi: 10.1038/s41467-019-12628-1.
3. Chen R, Zinzani PL, Lee HJ, Armand P, **Johnson NA**, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. *Blood.* 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.
4. Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, **Johnson NA**, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. *J Clin Oncol.* 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.
5. Tessier-Cloutier B, Twa DD, Baecklund E, Gascoyne R, **Johnson NA**, Backlin C, Kamen DL, Clarke AE, Ramsey-Goldman R, Lee JL, Farinha P, Bernatsky S. Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. *Lupus Sci Med.* 2019 May 4;6(1):e000324. doi: 10.1136/lupus-2019-000324. eCollection 2019.
6. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, **Johnson NA**, Miller WH Jr. Alectuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. *N Engl J Med.* 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. No abstract available.
7. Walcott-Sapp S, Garreau J, **Johnson N**, Thomas KA. Pathology results of architectural distortion on detected with digital breast tomosynthesis without definite sonographic correlate. *Am J Surg.* 2019 May;217(5):857-861. doi: 10.1016/j.amjsurg.2019.01.029. Epub 2019 Jan 31.
8. Sutton T, Farinola M, **Johnson N**, Garreau JR. Atypical ductal hyperplasia: Clinicopathologic factors are not predictive of upgrade after excisional biopsy. *Am J Surg.* 2019 May;217(5):848-850. doi: 10.1016/j.amjsurg.2018.12.020. Epub 2018 Dec 17.

### Petr Kavan

1. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, **Kavan P**, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. *J Clin Oncol.* 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.
2. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, **Kavan P**, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH,

- Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. *JAMA Oncol.* 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print] Erratum in: *JAMA Oncol.* 2019 Oct 10;.
- Riechelmann RP, Srimuninnimit V, Bordonaro R, **Kavan P**, Di Bartolomeo M, Maiello E, Cicin I, García-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, Karthaus M, Aparicio J, Heinemann V, Picard P, Bury D, Drea E, Sobrero A. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). *Clin Colorectal Cancer.* 2019 Sep;18(3):183-191.e3. doi: 10.1016/j.clcc.2019.05.003. Epub 2019 May 15.
  - Aubin S, Rosberger Z, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, **Kavan P**. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. *J Adolesc Young Adult Oncol.* 2019 Apr;8(2):172-189. doi: 10.1089/jayao.2017.0101. Epub 2018 Nov 28.
  - Bennouna J, André T, Campion L, Huret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, **Kavan P**, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. *Clin Colorectal Cancer.* 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

### Neil Kopek

- Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet.* 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.
- Kim SP, Cohalan C, **Kopek N**, Enger SA. A guide to <sup>90</sup>Y radioembolization and its dosimetry. *Phys Med.* 2019 Dec;68:132-145. doi: 10.1016/j.ejmp.2019.09.236. Epub 2019 Nov 28. Review.
- Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, **Kopek N**, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. *Int J Radiat Oncol Biol Phys.* 2019 Dec 1;105(5):943-947. doi: 10.1016/j.ijrobp.2019.08.041. Epub 2019 Aug 27.
- Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, **Kopek N**, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients

with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet*. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11.

- Kennedy ED, Simunovic M, Jhaveri K, Kirsch R, Brierley J, Drolet S, Brown C, Vos PM, Xiong W, MacLean T, Kanthan S, Stotland P, Raphael S, Chow G, O'Brien CA, Cho C, Streutker C, Wong R, Schmocker S, Liberman S, Reinhold C, **Kopek N**, Marcus V, Bouchard A, Lavoie C, Morin S, Périgny M, Wright A, Neumann K, Clarke S, Patil NG, Arnason T, Williams L, McLeod R, Brown G, Mathieson A, Pooni A, Baxter NN. Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial. *JAMA Oncol*. 2019 Jul 1;5(7):961-966. doi: 10.1001/jamaoncol.2019.0186.
- Dawson LA, Winter KA, Katz AW, Schell MC, Brierley J, Chen Y, **Kopek N**, Crane CH, Willett CG. NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases. *Pract Radiat Oncol*. 2019 Jul - Aug;9(4):e386-e393. doi: 10.1016/j.prro.2019.02.013. Epub 2019 Feb 27.

#### **Antonis Koromilas**

- Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, Basik M, **Koromilas AE**. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. *Nat Commun*. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.
- Koromilas AE**. M(en)TORship lessons on life and death by the integrated stress response. *Biochim Biophys Acta Gen Subj*. 2019 Mar;1863(3):644-649. doi: 10.1016/j.bbagen.2018.12.009. Epub 2018 Dec 17. Review.

#### **Pierre Laneuville**

- Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, **Laneuville P**, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP). Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia. *Cancer*. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13.
- Hughes TP, **Laneuville P**, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. *Haematologica*. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.

#### **Magali Lecavalier-Barsoum**

- Lecavalier-Barsoum M**, Chaudary N, Han K, Pintilie M, Hill RP, Milosevic M. Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy. *Br J Cancer*. 2019 Oct;121(7):626. doi: 10.1038/s41416-019-0545-z.

2. **Lecavalier-Barsoum M**, Chaudary N, Han K, Pintilie M, Hill RP, Milosevic M. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy. *Br J Cancer*. 2019 Jul;121(3):249-256. doi: 10.1038/s41416-019-0497-3. Epub 2019 Jun 26. Erratum in: *Br J Cancer*. 2019 Aug 9;.

#### Ives Levesque

1. Ahmed Z, **Levesque IR**. Pharmacokinetic modeling of dynamic contrast-enhanced MRI using a reference region and input function tail. *Magn Reson Med*. 2020 Jan;83(1):286-298. doi: 10.1002/mrm.27913. Epub 2019 Aug 8.
2. Papaconstadopoulos P, **Levesque IR**, Aldelaijan S, O'Grady K, Devic S, Seuntjens J. Modeling the primary source intensity distribution: reconstruction and inter-comparison of six Varian TrueBeam sources. *Phys Med Biol*. 2019 Jul 2;64(13):135005. doi: 10.1088/1361-6560/ab1ccc.

#### Sender Liberman

1. Trépanier M, Valin-Thorburn A, Kouyoumdjian A, Dumitra T, Alhashemi M, Kaneva P, **Liberman AS**, Charlebois P, Stein BS, Fried GM, Feldman LS, Lee L. Intracorporeal versus extracorporeal anastomosis for right colectomy does not affect gastrointestinal recovery within an enhanced recovery after surgery program. *Surg Endosc*. 2019 Oct 23. doi: 10.1007/s00464-019-07204-z. [Epub ahead of print]
2. Chau J, Solomon J, **Liberman AS**, Charlebois P, Stein B, Lee L. Pelvic dimensions on preoperative imaging can identify poor-quality resections after laparoscopic low anterior resection for mid- and low rectal cancer. *Surg Endosc*. 2019 Oct 16. doi: 10.1007/s00464-019-07209-8. [Epub ahead of print]
3. Trepanier M, Paradis T, Kouyoumdjian A, Dumitra T, Charlebois P, Stein BS, **Liberman AS**, Schwartzman K, Carli F, Fried GM, Feldman LS, Lee L. The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients. *J Gastrointest Surg*. 2020 Jan;24(1):115-122. doi: 10.1007/s11605-019-04328-4. Epub 2019 Jul 31.
4. Karimian N, Kaneva P, Donatelli F, Stein B, **Liberman AS**, Charlebois P, Lee L, Fiore JF Jr, Carli F, Feldman LS. Simple Versus Complex Preoperative Carbohydrate Drink to Preserve Perioperative Insulin Sensitivity in Laparoscopic Colectomy: A Randomized Controlled Trial. *Ann Surg*. 2019 Jul 26. doi: 10.1097/SLA.0000000000003488. [Epub ahead of print]
5. Trepanier M, Alhassan N, Sabapathy CA, **Liberman AS**, Charlebois P, Stein BL, S Feldman L, Lee L. Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective. *Dis Colon Rectum*. 2019 Nov;62(11):1381-1389. doi: 10.1097/DCR.0000000000001438.
6. Dickson EA, Penna M, Cunningham C, Ratcliffe FM, Chantler J, Crabtree NA, Tuynman JB, Albert MR, Monson JRT, Hompes R; International TaTME Registry Collaborative. Carbon Dioxide Embolism Associated With Transanal Total Mesorectal Excision Surgery: A Report From the International Registries. *Dis Colon Rectum*. 2019 Jul;62(7):794-801. doi: 10.1097/DCR.0000000000001410.
7. Minnella EM, **Liberman AS**, Charlebois P, Stein B, Scheede-Bergdahl C, Awasthi R, Gillis C, Bousquet-Dion G, Ramanakuma AV, Pecorelli N, Feldman LS, Carli F. The impact of improved functional capacity before surgery on postoperative complications: a



- study in colorectal cancer. *Acta Oncol.* 2019 May;58(5):573-578. doi: 10.1080/0284186X.2018.1557343. Epub 2019 Feb 6.
8. Pecorelli N, Balvardi S, **Liberman AS**, Charlebois P, Stein B, Carli F, Feldman LS, Fiore JF Jr. Does adherence to perioperative enhanced recovery pathway elements influence patient-reported recovery following colorectal resection? *Surg Endosc.* 2019 Nov;33(11):3806-3815. doi: 10.1007/s00464-019-06684-3. Epub 2019 Jan 30.
  9. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, **Liberman AS**, Charlebois P, Stein B, Carli F, Mayo NE, Feldman LS, Fiore JF Jr. Construct Validity and Responsiveness of the Abdominal Surgery Impact Scale in the Context of Recovery After Colorectal Surgery. *Dis Colon Rectum.* 2019 Mar;62(3):309-317. doi: 10.1097/DCR.0000000000001288.
  10. Alhashemi M, Fiore JF Jr, Safa N, Al Mahroos M, Mata J, Pecorelli N, Baldini G, Dendukuri N, Stein BL, **Liberman AS**, Charlebois P, Carli F, Feldman LS. Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway. *Surg Endosc.* 2019 Jul;33(7):2313-2322. doi: 10.1007/s00464-018-6514-4. Epub 2018 Oct 17.
  11. Alhassan N, Yang M, Wong-Chong N, **Liberman AS**, Charlebois P, Stein B, Fried GM, Lee L. Comparison between conventional colectomy and complete mesocolic excision for colon cancer: a systematic review and pooled analysis : A review of CME versus conventional colectomies. *Surg Endosc.* 2019 Jan;33(1):8-18. doi: 10.1007/s00464-018-6419-2. Epub 2018 Sep 12.
  12. Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loïselle SÈ, **Liberman AS**, Stein B, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. *Clin Nutr.* 2019 Jun;38(3):1053-1060. doi: 10.1016/j.clnu.2018.06.982. Epub 2018 Jul 9.
  13. Lee L, de Lacy B, Gomez Ruiz M, **Liberman AS**, Albert MR, Monson JRT, Lacy A, Kim SH, Atallah SB. A Multicenter Matched Comparison of Transanal and Robotic Total Mesorectal Excision for Mid and Low-rectal Adenocarcinoma. *Ann Surg.* 2019 Dec;270(6):1110-1116. doi: 10.1097/SLA.0000000000002862.

### Carmen Loïselle

1. Wu Y, Levis B, Sun Y, Krishnan A, He C, Riehm KE, Rice DB, Azar M, Yan XW, Neupane D, Bhandari PM, Imran M, Chiovitti MJ, Saadat N, Boruff JT, Cuijpers P, Gilbody S, McMillan D, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Henry M, Ismail Z, **Loïselle CG**, Mitchell ND, Tonelli M, Al-Adawi S, Beraldi A, Braeken APBM, Büel-Drabe N, Bunevicius A, Carter G, Chen CK, Cheung G, Clover K, Conroy RM, Cukor D, da Rocha E Silva CE, Dabscheck E, Daray FM, Douven E, Downing MG, Feinstein A, Ferentinos PP, Fischer FH, Flint AJ, Fujimori M, Gallagher P, Gandy M, Goebel S, Grassi L, Härter M, Jenewein J, Jetté N, Julião M, Kim JM, Kim SW, Kjærgaard M, Köhler S, Loosman WL, Löwe B, Martin-Santos R, Massardo L, Matsuoka Y, Mehnert A, Michopoulos I, Misery L, Navines R, O'Donnell ML, Öztürk A, Peceliuniene J, Pintor L, Ponsford JL, Quinn TJ, Reme SE, Reuter K, Rooney AG, Sánchez-González R, Schwarzbald ML, Senturk Cankorur V, Shaaban J, Sharpe L, Sharpe M, Simard S, Singer S, Stafford L, Stone J, Sultan S, Teixeira AL, Tiringier I, Turner A, Walker J, Walterfang M, Wang LJ, White J, Wong DK, Benedetti A, Thombs BD. Probability of major depression diagnostic classification based on the SCID, CIDI

and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale - Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. *J Psychosom Res.* 2020 Feb;129:109892. doi: 10.1016/j.jpsychores.2019.109892. Epub 2019 Dec 13.

2. **Loiselle CG.** Cancer information-seeking preferences linked to distinct patient experiences and differential satisfaction with cancer care. *Patient Educ Couns.* 2019 Jun;102(6):1187-1193. doi: 10.1016/j.pec.2019.01.009. Epub 2019 Jan 18.
3. **Loiselle CG,** Howell D, Nicoll I, Fitch M. Toward the development of a comprehensive cancer experience measurement framework. *Support Care Cancer.* 2019 Jul;27(7):2579-2589. doi: 10.1007/s00520-018-4529-y. Epub 2018 Nov 16. Review.
4. Lambert SD, Ould Brahim L, Morrison M, Girgis A, Yaffe M, Belzile E, Clayberg K, Robinson J, Thorne S, Bottorff JL, Duggleby W, Campbell-Enns H, Kim Y, **Loiselle CG.** Priorities for caregiver research in cancer care: an international Delphi survey of caregivers, clinicians, managers, and researchers. *Support Care Cancer.* 2019 Mar;27(3):805-817. doi: 10.1007/s00520-018-4314-y. Epub 2018 Jul 31.

### **Koren Mann**

1. VanderSchee CR, Kuter D, Chou H, Jackson BP, **Mann KK,** Bohle DS. Addressing K/L-edge overlap in elemental analysis from micro-X-ray fluorescence: bioimaging of tungsten and zinc in bone tissue using synchrotron radiation and laser ablation inductively coupled plasma mass spectrometry. *Anal Bioanal Chem.* 2019 Nov 27. doi: 10.1007/s00216-019-02244-9. [Epub ahead of print]
2. Di Lenardo TZ, Ward BJ, Pillet S, **Mann K,** Bornman R, Obida M, Chevrier J. Exposure to lead and vaccine-specific IgG titers in South African children participating in the Venda Health Examination of Mothers, Babies and their Environment (VHEMBE): A longitudinal study. *Environ Res.* 2020 Jan;180:108794. doi: 10.1016/j.envres.2019.108794. Epub 2019 Oct 9.
3. Wu TH, Bolt AM, Chou H, Plourde D, De Jay N, Guilbert C, Young YK, Kleinman CL, **Mann KK.** Tungsten Blocks Murine B Lymphocyte Differentiation and Proliferation Through Downregulation of IL-7 Receptor/Pax5 Signaling. *Toxicol Sci.* 2019 Jul 1;170(1):45-56. doi: 10.1093/toxsci/kfz080.

### **Luke McCaffrey**

1. Catterall R, Lelarge V, **McCaffrey L.** Genetic alterations of epithelial polarity genes are associated with loss of polarity in invasive breast cancer. *Int J Cancer.* 2020 Mar 15;146(6):1578-1591. doi: 10.1002/ijc.32691. Epub 2019 Oct 30.
2. Chatterjee SJ, Halaoui R, Deagle RC, Rejon C, **McCaffrey L.** Numb regulates cell tension required for mammary duct elongation. *Biol Open.* 2019 May 30;8(5). pii: bio042341. doi: 10.1242/bio.042341.
3. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, **McCaffrey L,** Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma *In Situ.* *Cancer Res.* 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.

- Lee W, Kalashnikov N, Mok S, Halaoui R, Kuzmin E, Putnam AJ, Takayama S, Park M, **McCaffrey L**, Zhao R, Leask RL, Moraes C. Dispersible hydrogel force sensors reveal patterns of solid mechanical stress in multicellular spheroid cultures. *Nat Commun.* 2019 Jan 11;10(1):144. doi: 10.1038/s41467-018-07967-4.
- Toss MS, Miligy IM, Gorringer KL, **McCaffrey L**, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. *Mod Pathol.* 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

#### **Ari Meguerditchian**

- Tamblyn R, Abrahamowicz M, Buckeridge DL, Bustillo M, Forster AJ, Girard N, Habib B, Hanley J, Huang A, Kurteva S, Lee TC, **Meguerditchian AN**, Moraga T, Motulsky A, Petrella L, Weir DL, Winslade N. Effect of an Electronic Medication Reconciliation Intervention on Adverse Drug Events: A Cluster Randomized Trial. *JAMA Netw Open.* 2019 Sep 4;2(9):e1910756. doi: 10.1001/jamanetworkopen.2019.10756.

#### **Sarkis Meterissian**

- St-Louis E, Shaheen M, Mukhtar F, Adessky R, **Meterissian S**, Boutros M. Towards Development of an Open Surgery Competency Assessment for Residents (OSCAR) Tool - A Systematic Review of the Literature and Delphi Consensus. *J Surg Educ.* 2019 Dec 27. pii: S1931-7204(19)30536-7. doi: 10.1016/j.jsurg.2019.10.006. [Epub ahead of print]
- Morency D, Dumitra S, Parvez E, Martel K, Basik M, Robidoux A, Poirier B, Holloway CMB, Gaboury L, Sideris L, **Meterissian S**, Boileau JF. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study. *Ann Surg Oncol.* 2019 Dec;26(13):4337-4345. doi: 10.1245/s10434-019-07809-7. Epub 2019 Oct 11.
- Lagacé F, Ghazawi FM, Le M, Rahme E, Savin E, Zubarev A, Alakel A, Sasseville D, Moreau L, **Meterissian S**, Litvinov IV. Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada. *Breast Cancer Res Treat.* 2019 Dec;178(3):683-691. doi: 10.1007/s10549-019-05418-2. Epub 2019 Sep 4.
- Sabiston CM, Fong AJ, O'Loughlin EK, **Meterissian S**. A mixed-methods evaluation of a community physical activity program for breast cancer survivors. *J Transl Med.* 2019 Jun 19;17(1):206. doi: 10.1186/s12967-019-1958-4.
- Yu N, Leung VWY, **Meterissian S**. MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer. *World J Surg.* 2019 Sep;43(9):2254-2261. doi: 10.1007/s00268-019-05032-9. Review.
- Savage P, Yu N, Dumitra S, **Meterissian S**. The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication. *Eur J Surg Oncol.* 2019 Oct;45(10):1817-1820. doi: 10.1016/j.ejso.2019.03.027. Epub 2019 Mar 23.
- Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM, Monette A, Ramos VM, Hallett MT, Stagg J, Lapointe R, Omeroglu A, **Meterissian S**, Buisseret L, Van den Eynden G, Salgado R, Guiot MC, Haibe-Kains B, Park M. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. *J Clin Invest.* 2019 Apr 1;129(4):1785-1800. doi: 10.1172/JCI96313. Epub 2019 Mar 18.

- Li X, Gruosso T, Zuo D, Omeroglu A, **Meterissian S**, Guiot MC, Salazar A, Park M, Levine H. Infiltration of CD8<sub>+</sub> T cells into tumor cell clusters in triple-negative breast cancer. *Proc Natl Acad Sci U S A*. 2019 Feb 26;116(9):3678-3687. doi: 10.1073/pnas.1817652116. Epub 2019 Feb 7.
- Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, **Meterissian S**. Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. *World J Surg*. 2019 May;43(5):1264-1270. doi: 10.1007/s00268-018-04897-6. Review.

#### Catalin Mihalcioiu

- Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, **Mihalcioiu C**, Majewski J, Basik M. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. *Mol Cancer Res*. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.
- Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, **Mihalcioiu C**, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Oncol*. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514. Erratum in: *JAMA Oncol*. 2019 Feb 1;5(2):271.

#### Wilson Miller

- Hellmann MD, Kim TW, Lee CB, Goh BC, **Miller WH Jr**, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. *Ann Oncol*. 2019 Jul;30(7):1134-1142. doi: 10.1093/annonc/mdz113. Epub 2019 Dec 4.
- Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, **Miller WH Jr**, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. *J Thorac Oncol*. 2019 Dec 20. pii: S1556-0864(19)33850-X. doi: 10.1016/j.jtho.2019.12.109. [Epub ahead of print]
- Abdul Razak AR, **Miller WH Jr**, Uy GL, Blotner S, Young AM, Higgins B, Chen LC, Gore L. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. *Invest New Drugs*. 2019 Nov 16. doi: 10.1007/s10637-019-00869-2. [Epub ahead of print]

4. Ribas A, Lawrence D, Atkinson V, Agarwal S, **Miller WH Jr**, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghorri R, Moreno BH, Ibrahim N, Hamid O. Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nat Med*. 2019 Aug;25(8):1319. doi: 10.1038/s41591-019-0535-y.
5. Kumar R, de Vijver MV, Tortora G, Ciardiello F, Goldkorn T, **Miller WH Jr**, Norton L. A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. *Cancer Res*. 2019 Sep 1;79(17):4315-4323. doi: 10.1158/0008-5472.CAN-19-0989. Epub 2019 Jun 18. Review.
6. Guo Q, Huang F, Goncalves C, Del Rincón SV, **Miller WH Jr**. Translation of cancer immunotherapy from the bench to the bedside. *Adv Cancer Res*. 2019;143:1-62. doi: 10.1016/bs.acr.2019.03.001. Epub 2019 May 2.
7. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, **Miller WH Jr**. Alectuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. *N Engl J Med*. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. No abstract available.
8. Ribas A, Lawrence D, Atkinson V, Agarwal S, **Miller WH Jr**, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghorri R, Moreno BH, Ibrahim N, Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nat Med*. 2019 Jun;25(6):936-940. doi: 10.1038/s41591-019-0476-5. Epub 2019 Jun 6. Erratum in: *Nat Med*. 2019 Aug;25(8):1319.
9. Mazulis CA, Erb HN, Thachil A, **Miller WH Jr**. External ear cytological results and resident flora of clinically normal alpacas (*Vicugna pacos*). *Vet Dermatol*. 2019 Aug;30(4):337-e94. doi: 10.1111/vde.12751. Epub 2019 Apr 30.
10. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, **Miller WH Jr**, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
11. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, **Miller WH Jr**. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma *In Situ*. *Cancer Res*. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
12. Esfahani K, Meti N, **Miller WH Jr**, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. *CMAJ*. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870. Review. No abstract available.

### **Elliot Mitmaker**

1. Madani A, Grover K, Kuo JH, **Mitmaker EJ**, Shen W, Beninato T, Livhits M, Smith PW, Miller BS, Sippel RS, Duh QY, Lee JA. Defining the competencies for laparoscopic transabdominal adrenalectomy: An investigation of intraoperative behaviors and

- decisions of experts. *Surgery*. 2020 Jan;167(1):241-249. doi: 10.1016/j.surg.2019.03.035. Epub 2019 Oct 22.
2. Vorselaars WMCM, van Beek DJ, Postma EL, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR; **International CONNsortium Study Group**. Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice. *World J Surg*. 2019 Oct;43(10):2459-2468. doi: 10.1007/s00268-019-05074-z. Erratum in: *World J Surg*. 2019 Sep 5;.
  3. Vorselaars WMCM, van Beek DJ, Postma EL, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR; **International CONNsortium study group**. Clinical outcomes after surgery for primary aldosteronism: Evaluation of the PASO-investigators' consensus criteria within a worldwide cohort of patients. *Surgery*. 2019 Jul;166(1):61-68. doi: 10.1016/j.surg.2019.01.031. Epub 2019 May 1.
  4. Pancer J, **Mitmaker E**, Ajise O, Tabah R, How J. A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation. *Endocrinol Diabetes Metab Case Rep*. 2019 Mar 18;2019. pii: EDM190006. doi: 10.1530/EDM-19-0006. [Epub ahead of print]
  5. Vorselaars WMCM, Nell S, Postma EL, Zarnegar R, Drake FT, Duh QY, Talutis SD, McAneny DB, McManus C, Lee JA, Grant SB, Grogan RH, Romero Arenas MA, Perrier ND, Peipert BJ, Mongelli MN, Castolino T, **Mitmaker EJ**, Parente DN, Pasternak JD, Engelsman AF, Sywak M, D'Amato G, Raffaelli M, Schuermans V, Bouvy ND, Eker HH, Bonjer HJ, Vaarzon Morel NM, Nieveen van Dijkum EJM, Vrieling OM, Kruijff S, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR; International CONNsortium study group. Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism. *JAMA Surg*. 2019 Apr 1;154(4):e185842. doi: 10.1001/jamasurg.2018.5842. Epub 2019 Apr 17.
  6. **Mitmaker EJ**, Tabah R, How J. Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation. *Clin Cancer Res*. 2019 Jan 15;25(2):457-459. doi: 10.1158/1078-0432.CCR-18-2820. Epub 2018 Oct 16.

### Thierry Muanza

1. Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, **Muanza T**, Beckham WA, Chua BH, Gu CS, Levine MN, Olivetto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet*. 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.
2. Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, Greenwood CMT, Basik M, **Muanza TM**. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. *Sci Rep*. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.

### Alain Nepveu

1. Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, **Nepveu A**, Maciejewski JP. Distinct clinical and biological

implications of *CUX1* in myeloid neoplasms. *Blood Adv.* 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.

### Tamim Niazi

1. So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, **Niazi T**, Pouliot F, Rendon RA, Shayegan B, Sridhar S, Vigneault E, Saad F. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. *Can Urol Assoc J.* 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5. No abstract available.
2. Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B, So AI, Aaron L, Basappa NS, Conter HJ, Danielson B, Gotto G, Hamilton RJ, Izard JP, Kapoor A, Kolinsky M, Lalani AA, Lattouf JB, Morash C, Morgan SC, **Niazi T**, Noonan KL, Ong M, Rendon RA, Sehdev S, Hew H, Park-Wyllie L, Chi KN. A Canadian consensus forum on the management of patients with advanced prostate cancer. *Can Urol Assoc J.* 2019 Nov 5. doi: 10.5489/cuaj.6082. [Epub ahead of print] Review.
3. Rathore S, Iftikhar MA, Chaddad A, **Niazi T**, Karasic T, Bilello M. Segmentation and Grade Prediction of Colon Cancer Digital Pathology Images Across Multiple Institutions. *Cancers (Basel).* 2019 Nov 1;11(11). pii: E1700. doi: 10.3390/cancers11111700.
4. Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, **Niazi T**, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, Chi KN. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J.* 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136. No abstract available.
5. Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, **Niazi T**, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). *Can Urol Assoc J.* 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.
6. Ghashghaei M, **Niazi TM**, Aguilar-Mahecha A, Klein KO, Greenwood CMT, Basik M, Muanza TM. Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells. *Sci Rep.* 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.
7. Chaddad A, Kucharczyk MJ, Daniel P, Sabri S, Jean-Claude BJ, **Niazi T**, Abdulkarim B. Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation. *Front Oncol.* 2019 May 21;9:374. doi: 10.3389/fonc.2019.00374. eCollection 2019. Review.
8. Elakshar S, Tsui JMG, Kucharczyk MJ, Tomic N, Fawaz ZS, Bahoric B, Papayanatos J, Chaddad A, **Niazi T**. Does Interfraction Cone Beam Computed Tomography Improve Target Localization in Prostate Bed Radiotherapy? *Technol Cancer Res Treat.* 2019 Jan 1;18:1533033819831962. doi: 10.1177/1533033819831962. Erratum in: *Technol Cancer Res Treat.* 2019 Jan 1;18:1533033819846992.
9. Kucharczyk MJ, Gravis G, **Niazi T**. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer. *Eur Urol Focus.* 2019 Mar;5(2):117-118. doi: 10.1016/j.euf.2018.11.011. Epub 2018 Dec 4.

### Alexandre Orthwein

1. Sherill-Rofe D, Rahat D, Findlay S, Mellul A, Guberman I, Braun M, Bloch I, Lalezari A, Samiei A, Sadreyev R, Goldberg M, **Orthwein A**, Zick A, Tabach Y. Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes. *Genome Res.* 2019 Mar;29(3):439-448. doi: 10.1101/gr.241414.118. Epub 2019 Feb 4.

### Lawrence Panasci

1. Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; **PERUSE investigators.** Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Ann Oncol.* 2019 May;30(5):766-773. doi: 10.1093/annonc/mdz061. Epub 2019 Dec 4.
2. Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; **RAPID Trial Investigators.** External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet.* 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.

### Valerie Panet-Raymond

1. Rodrigues G, Yartsev S, Roberge D, MacRae R, Roa WH, **Panet-Raymond V**, Masucci GL, Yaremko BP, D'Souza D, Palma D, Sexton T, Yu E, Pantarotto J, Ahmad B, Fisher B, Dar AR, Lambert C, Pond G, Tay KY, Bauman G. A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. *Cureus.* 2019 Dec 16;11(12):e6394. doi: 10.7759/cureus.6394.
2. Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; **RAPID Trial Investigators.** External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet.* 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.
3. Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, **Panet-Raymond V**, McMillan WG, de Groot JF, Zhang P, Mehta MP. High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. *Int J Radiat Oncol Biol Phys.* 2019 Nov 28. pii: S0360-3016(19)34067-2. doi: 10.1016/j.ijrobp.2019.11.028. [Epub ahead of print]
4. **Panet-Raymond V**, Sabit K, Shenouda G, Sirhan D, Zeitouni A, Souhami L. Growth of Pituitary Macroadenomas Postpartial Resection: Implications for Adjuvant Radiotherapy. *J Neurol Surg B Skull Base.* 2019 Jun;80(3):323-326. doi: 10.1055/s-0038-1670686. Epub 2018 Oct 10.



5. Khayat HA, Al-Saadi T, **Panet-Raymond V**, Diaz RJ. Surgical Management of Isolated Fourth Ventricular Hydrocephalus Associated with Injury to the Guillain-Mollaret Triangle. *World Neurosurg*. 2019 Feb;122:71-76. doi: 10.1016/j.wneu.2018.10.091. Epub 2018 Oct 25.

### Morag Park

1. Bell ES, Coelho PP, Ratcliffe CDH, Rajadurai CV, Peschard P, Vaillancourt R, Zuo D, **Park M**. LC3C-Mediated Autophagy Selectively Regulates the Met RTK and HGF-Stimulated Migration and Invasion. *Cell Rep*. 2019 Dec 17;29(12):4053-4068.e6. doi: 10.1016/j.celrep.2019.11.063.
2. Kong T, Ahn R, Yang K, Zhu X, Fu Z, Morin G, Bramley R, Cliffe NC, Xue Y, Kuasne H, Li Q, Jung S, Gonzalez AV, Camilleri-Broët S, Guiot MC, **Park M**, Ursini-Siegel J, Huang S. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. *Cancer Res*. 2019 Nov 13. pii: canres.1108.2019. doi: 10.1158/0008-5472.CAN-19-1108. [Epub ahead of print]
3. Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, **Park M**, Rothé F, Stagg J, Sotiriou C. Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. *J Natl Cancer Inst*. 2019 Oct 29. pii: djz208. doi: 10.1093/jnci/djz208. [Epub ahead of print]
4. Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, **Park M**, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, Muller WJ. Reduction of Global H3K27me<sub>3</sub> Enhances HER2/ErbB2 Targeted Therapy. *Cell Rep*. 2019 Oct 8;29(2):249-257.e8. doi: 10.1016/j.celrep.2019.08.105.
5. Zaoui K, Rajadurai CV, Duhamel S, **Park M**. Arf6 regulates RhoB subcellular localization to control cancer cell invasion. *J Cell Biol*. 2019 Nov 4;218(11):3812-3826. doi: 10.1083/jcb.201806111. Epub 2019 Oct 7.
6. Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, Foulkes WD, Porco JA Jr, **Park M**, Pelletier J, Huang S. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. *Mol Cancer Ther*. 2019 Nov;18(11):2158-2170. doi: 10.1158/1535-7163.MCT-19-0162. Epub 2019 Aug 8.
7. Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, **Park M**, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. An ErbB2/c-*Src* axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. *Nat Commun*. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.
8. Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM, Monette A, Ramos VM, Hallett MT, Stagg J, Lapointe R, Omeroglu A, Meterissian S, Buisseret L, Van den Eynden G, Salgado R, Guiot MC, Haibe-Kains B, **Park M**. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. *J Clin Invest*. 2019 Apr 1;129(4):1785-1800. doi: 10.1172/JCI96313. Epub 2019 Mar 18.

9. Li X, Gruosso T, Zuo D, Omeroglu A, Meterissian S, Guiot MC, Salazar A, **Park M**, Levine H. Infiltration of CD8<sub>+</sub> T cells into tumor cell clusters in triple-negative breast cancer. *Proc Natl Acad Sci U S A*. 2019 Feb 26;116(9):3678-3687. doi: 10.1073/pnas.1817652116. Epub 2019 Feb 7.
10. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, **Park M**, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun*. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
11. Lee W, Kalashnikov N, Mok S, Halaoui R, Kuzmin E, Putnam AJ, Takayama S, **Park M**, McCaffrey L, Zhao R, Leask RL, Moraes C. Dispersible hydrogel force sensors reveal patterns of solid mechanical stress in multicellular spheroid cultures. *Nat Commun*. 2019 Jan 11;10(1):144. doi: 10.1038/s41467-018-07967-4.
12. Zaoui K, Duhamel S, Parachoniak CA, **Park M**. CLIP-170 spatially modulates receptor tyrosine kinase recycling to coordinate cell migration. *Traffic*. 2019 Mar;20(3):187-201. doi: 10.1111/tra.12629. Epub 2019 Jan 15.
13. HGF-induced migration depends on the PI(3,4,5)P<sub>3</sub>-binding microexon-spliced variant of the Arf6 exchange factor cytohesin-1. Ratcliffe CDH, Siddiqui N, Coelho PP, Laterreur N, Cookey TN, Sonenberg N, **Park M**. *J Cell Biol*. 2019 Jan 7;218(1):285-298. doi: 10.1083/jcb.201804106. Epub 2018 Nov 7.

#### **William Parker**

1. Serban M, Lambert C, Ruo R, Maietta C, **Parker W**, Evans M, Hijal T. Computed tomography-based virtual simulation versus ultrasound-based clinical setup in electron breast boost radiotherapy: Methodology for CT-based electron virtual simulation. *Phys Med*. 2019 Nov;67:100-106. doi: 10.1016/j.ejmp.2019.10.030. Epub 2019 Nov 6.
2. Videtic GM, Paulus R, Singh AK, Chang JY, **Parker W**, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 2019 Apr 1;103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1.
3. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, **Parker W**, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. *J Clin Oncol*. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.

#### **François Patenaude**

1. Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T,

Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; **RAPID Trial Investigators**. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. *Lancet*. 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.

- Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DY, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, **Patenaude F**, Soulières D, Violette P, Winkvist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. *Can Urol Assoc J*. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. No abstract available.

### Jerry Pelletier

- Shen L, **Pelletier J**. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products. *Nat Prod Rep*. 2019 Nov 29. doi: 10.1039/c9np00052f. [Epub ahead of print]
- Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas CJ, Brown LE, Porco JA Jr, Pollak M, Larsson O, **Pelletier J**, Chio IIC. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nat Commun*. 2019 Nov 13;10(1):5151. doi: 10.1038/s41467-019-13086-5.
- Chu J, Zhang W, Cencic R, Devine WG, Beglov D, Henkel T, Brown LE, Vajda S, Porco JA Jr, **Pelletier J**. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors. *Cell Chem Biol*. 2019 Nov 21;26(11):1586-1593.e3. doi: 10.1016/j.chembiol.2019.08.008. Epub 2019 Sep 10.
- Gonçalves AC, Towers ER, Haq N, Porco JA Jr, **Pelletier J**, Dawson SJ, Gale JE. Drug-induced Stress Granule Formation Protects Sensory Hair Cells in Mouse Cochlear Explants During Ototoxicity. *Sci Rep*. 2019 Aug 29;9(1):12501. doi: 10.1038/s41598-019-48393-w.
- Dauber B, **Pelletier J**, Smiley JR. Correction for Dauber et al., "The Herpes Simplex Virus 1 vhs Protein Enhances Translation of Viral True Late mRNAs and Virus Production in a Cell Type-Dependent Manner". *J Virol*. 2019 Aug 13;93(17). pii: e00985-19. doi: 10.1128/JVI.00985-19. Print 2019 Sep 1. No abstract available.
- Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, Foulkes WD, Porco JA Jr, Park M, **Pelletier J**, Huang S. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. *Mol Cancer Ther*. 2019 Nov;18(11):2158-2170. doi: 10.1158/1535-7163.MCT-19-0162. Epub 2019 Aug 8.
- Nyandoro SS, Maeda G, Munissi JJE, Gruhonjic A, Fitzpatrick PA, Lindblad S, Duffy S, **Pelletier J**, Pan F, Puttreddy R, Avery VM, Erdélyi M. A New Benzopyranyl Cadenane Sesquiterpene and Other Antiplasmodial and Cytotoxic Metabolites from *Cleistochlamys kirkii*. *Molecules*. 2019 Jul 29;24(15). pii: E2746. doi: 10.3390/molecules24152746.
- Zhang W, Chu J, Cyr AM, Yueh H, Brown LE, Wang TT, **Pelletier J**, Porco JA Jr. Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and

- Their Biological Evaluation as eIF4A Inhibitors. *J Am Chem Soc.* 2019 Aug 14;141(32):12891-12900. doi: 10.1021/jacs.9b06446. Epub 2019 Jul 30.
9. **Pelletier J**, Sonenberg N. The Organizing Principles of Eukaryotic Ribosome Recruitment. *Annu Rev Biochem.* 2019 Jun 20;88:307-335. doi: 10.1146/annurev-biochem-013118-111042.
  10. Li X, Zhu Q, Shi X, Cheng Y, Li X, Xu H, Duan X, Hsieh-Wilson LC, Chu J, **Pelletier J**, Ni M, Zheng Z, Li S, Yi W. O-GlcNAcylation of core components of the translation initiation machinery regulates protein synthesis. *Proc Natl Acad Sci U S A.* 2019 Apr 16;116(16):7857-7866. doi: 10.1073/pnas.1813026116. Epub 2019 Apr 2.
  11. Steinberger J, Robert F, Hallé M, Williams DE, Cencic R, Sawhney N, Pelletier D, Williams P, Igarashi Y, Porco JA Jr, Rodriguez AD, Kopp B, Bachmann B, Andersen RJ, **Pelletier J**. Tracing MYC Expression for Small Molecule Discovery. *Cell Chem Biol.* 2019 May 16;26(5):699-710.e6. doi: 10.1016/j.chembiol.2019.02.007. Epub 2019 Mar 14.
  12. Itoua Maïga R, Cencic R, Chu J, Waller DD, Brown LE, Devine WG, Zhang W, Sebag M, Porco JA Jr, **Pelletier J**. Oxo-aglaistatin-Mediated Inhibition of Translation Initiation. *Sci Rep.* 2019 Feb 4;9(1):1265. doi: 10.1038/s41598-018-37666-5.
  13. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, **Pelletier J**, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun.* 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
  14. Hardy S, Kostantin E, Wang SJ, Hristova T, Galicia-Vázquez G, Baranov PV, **Pelletier J**, Tremblay ML. Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism. *Proc Natl Acad Sci U S A.* 2019 Feb 19;116(8):2925-2934. doi: 10.1073/pnas.1815361116. Epub 2019 Feb 4.
  15. Lin YH, Forster M, Liang Y, Yu M, Wang H, Robert F, Langlais D, **Pelletier J**, Clare S, Nijnik A. USP44 is dispensable for normal hematopoietic stem cell function, lymphocyte development, and B-cell-mediated immune response in a mouse model. *Exp Hematol.* 2019 Apr;72:1-8. doi: 10.1016/j.exphem.2019.01.001. Epub 2019 Jan 9.
  16. Zhang W, Liu S, Maiga RI, **Pelletier J**, Brown LE, Wang TT, Porco JA Jr. Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection. *J Am Chem Soc.* 2019 Jan 23;141(3):1312-1323. doi: 10.1021/jacs.8b11477. Epub 2019 Jan 11.

### Michael Pollak

1. Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Hercberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, Mucci LA, Neal DE, Neuhauser ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, **Pollak M**, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis

- KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. *Int J Cancer*. 2019 Dec 15;145(12):3244-3256. doi: 10.1002/ijc.32276. Epub 2019 Apr 4. PubMed PMID: 30873591; PubMed Central PMCID: PMC6745281.
2. Lord SR, Collins JM, Cheng WC, Haider S, Wigfield S, Gaude E, Fielding BA, Pinnick KE, Harjes U, Segaran A, Jha P, Hoefler G, **Pollak MN**, Thompson AM, Roy PG, English R, Adams RF, Frezza C, Buffa FM, Karpe F, Harris AL. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. *Br J Cancer*. 2019 Dec 10;. doi: 10.1038/s41416-019-0665-5. [Epub ahead of print] PubMed PMID: 31819193.
  3. Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, Rodriguez LM, Szabo E, Ford LG, **Pollak MN**, Meyskens FL. A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. *Cancer Prev Res (Phila)*. 2019 Dec 9;. doi: 10.1158/1940-6207.CAPR-18-0262. [Epub ahead of print] PubMed PMID: 31818851.
  4. Molenaar RJ, van Hattum JW, Brummelhuis IS, Oddens JR, Savci-Heijink CD, Boevé ER, van der Meer SA, Witjes JF, **Pollak MN**, de Reijke TM, Wilmink JW. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. *BMC Cancer*. 2019 Nov 21;19(1):1133. doi: 10.1186/s12885-019-6346-1. PubMed PMID: 31752752; PubMed Central PMCID: PMC6873510.
  5. Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas CJ, Brown LE, Porco JA Jr, **Pollak M**, Larsson O, Pelletier J, Chio IIC. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nat Commun*. 2019 Nov 13;10(1):5151. doi: 10.1038/s41467-019-13086-5. PubMed PMID: 31723131; PubMed Central PMCID: PMC6853918.
  6. Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, **Pollak MN**, Ferrario C, Basik M. Metastatic breast carcinoma-associated fibroblasts have enhanced pro-tumorigenic properties related to increased IGF2 expression. *Clin Cancer Res*. 2019 Sep 12;. doi: 10.1158/1078-0432.CCR-19-1268. [Epub ahead of print] PubMed PMID: 31515454.
  7. Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, **Pollak M**, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. *J Natl Cancer Inst*. 2019 Sep 1;111(9):970-982. doi: 10.1093/jnci/djy209. PubMed PMID: 30698726; PubMed Central PMCID: PMC6748813.
  8. Münch NS, Fang HY, Ingermann J, Maurer HC, Anand A, Kellner V, Sahn V, Wiethaler M, Baumeister T, Wein F, Einwächter H, Bolze F, Klingenspor M, Haller D, Kavanagh M, Lysaght J, Friedman R, Dannenberg AJ, **Pollak M**, Holt PR, Muthupalani S, Fox JG, Whary MT, Lee Y, Ren TY, Elliot R, Fitzgerald R, Steiger K, Schmid RM, Wang TC, Quante M. High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's

- Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. *Gastroenterology*. 2019 Aug;157(2):492-506.e2. doi: 10.1053/j.gastro.2019.04.013. Epub 2019 Apr 15. PubMed PMID: 30998992; PubMed Central PMCID: PMC6662596.
9. Hada M, Oh H, Pfeiffer RM, Falk RT, Fan S, Mullooly M, **Pollak M**, Geller B, Vacek PM, Weaver D, Shepherd J, Wang J, Fan B, Mahmoudzadeh AP, Malkov S, Herschorn S, Brinton LA, Sherman ME, Gierach GL. Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. *Breast Cancer Res*. 2019 Jul 23;21(1):81. doi: 10.1186/s13058-019-1162-8. PubMed PMID: 31337427; PubMed Central PMCID: PMC6651938.
  10. Papadopoli D, Boulay K, Kazak L, **Pollak M**, Mallette F, Topisirovic I, Hulea L. mTOR as a central regulator of lifespan and aging. *F1000Res*. 2019;8. doi: 10.12688/f1000research.17196.1. eCollection 2019. Review. PubMed PMID: 31316753; PubMed Central PMCID: PMC6611156.
  11. Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, **Pollak M**, Manetsch G, Strebel R, Cathomas R. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. *Clin Genitourin Cancer*. 2019 Apr;17(2):e323-e328. doi: 10.1016/j.clgc.2018.12.009. Epub 2019 Jan 2. PubMed PMID: 30686756.
  12. Uchenunu O, **Pollak M**, Topisirovic I, Hulea L. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. *J Mol Endocrinol*. 2019 Feb 1;62(2):R83-R103. doi: 10.1530/JME-18-0058. Review. PubMed PMID: 30072418; PubMed Central PMCID: PMC6347283.
  13. DuBois RN, **Pollak MN**. Cancer Prevention: A Message from the New Editors-in-Chief. *Cancer Prev Res (Phila)*. 2019 Jan;12(1):1-2. doi: 10.1158/1940-6207.CAPR-18-0349. Epub 2018 Dec 27. PubMed PMID: 30591430.

### Stéphane Richard

1. Klein ME, Younts TJ, Cobo CF, Buxbaum AR, Aow J, Erdjument-Bromage H, **Richard S**, Malinow R, Neubert TA, Singer RH, Castillo PE, Jordan BA. Sam68 Enables Metabotropic Glutamate Receptor-Dependent LTD in Distal Dendritic Regions of CA1 Hippocampal Neurons. *Cell Rep*. 2019 Nov 12;29(7):1789-1799.e6. doi: 10.1016/j.celrep.2019.10.030.
2. Han S, Xu S, Zhou J, Qiao A, Boriboun C, Ma W, Li H, Biyashev D, Yang L, Zhang E, Liu Q, Jiang S, Zhao TC, Krishnamurthy P, Zhang C, **Richard S**, Qiu H, Zhang J, Qin G. Sam68 impedes the recovery of arterial injury by augmenting inflammatory response. *J Mol Cell Cardiol*. 2019 Dec;137:82-92. doi: 10.1016/j.yjmcc.2019.10.003. Epub 2019 Oct 19.
3. Qiao X, Kim DI, Jun H, Ma Y, Knights AJ, Park MJ, Zhu K, Lipinski JH, Liao J, Li Y, **Richard S**, Weinman SA, Wu J. Protein Arginine Methyltransferase 1 Interacts With PGC1 $\alpha$  and Modulates Thermogenic Fat Activation. *Endocrinology*. 2019 Dec 1;160(12):2773-2786. doi: 10.1210/en.2019-00504.
4. Wong TL, Ng KY, Tan KV, Chan LH, Zhou L, Che N, Hoo RLC, Lee TK, **Richard S**, Lo CM, Man K, Khong PL, Ma S. CRAF Methylation by PRMT6 Regulates Aerobic

- Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. *Hepatology*. 2019 Aug 30. doi: 10.1002/hep.30923. [Epub ahead of print]
5. Guccione E, **Richard S**. Author Correction: The regulation, functions and clinical relevance of arginine methylation. *Nat Rev Mol Cell Biol*. 2019 Sep;20(9):567. doi: 10.1038/s41580-019-0166-7.
  6. Guccione E, **Richard S**. The regulation, functions and clinical relevance of arginine methylation. *Nat Rev Mol Cell Biol*. 2019 Oct;20(10):642-657. doi: 10.1038/s41580-019-0155-x. Epub 2019 Jul 26. Review. Erratum in: *Nat Rev Mol Cell Biol*. 2019 Sep;20(9):567.
  7. Srouf N, Mersaoui SY, **Richard S**. M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge. *Cancer Cell*. 2019 Jul 8;36(1):3-5. doi: 10.1016/j.ccell.2019.06.004.
  8. Mersaoui SY, Yu Z, Coulombe Y, Karam M, Busatto FF, Masson JY, **Richard S**. Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids. *EMBO J*. 2019 Aug 1;38(15):e100986. doi: 10.15252/embj.2018100986. Epub 2019 Jun 21.
  9. Litzler LC, Zahn A, Meli AP, Hébert S, Patenaude AM, Methot SP, Sprumont A, Bois T, Kitamura D, Costantino S, King IL, Kleinman CL, **Richard S**, Di Noia JM. PRMT5 is essential for B cell development and germinal center dynamics. *Nat Commun*. 2019 Jan 3;10(1):22. doi: 10.1038/s41467-018-07884-6.

### **Zeev Rosberger**

1. Thompson EL, Galvin AM, Daley EM, Tatar O, Zimet GD, **Rosberger Z**. Recent changes in cervical cancer screening guidelines: U.S. women's willingness for HPV testing instead of Pap testing. *Prev Med*. 2020 Jan;130:105928. doi: 10.1016/j.ypmed.2019.105928. Epub 2019 Nov 19.
2. Tatar O, Wade K, McBride E, Thompson E, Head KJ, Perez S, Shapiro GK, Waller J, Zimet G, **Rosberger Z**. Are Health Care Professionals Prepared to Implement Human Papillomavirus Testing? A Review of Psychosocial Determinants of Human Papillomavirus Test Acceptability in Primary Cervical Cancer Screening. *J Womens Health (Larchmt)*. 2019 Sep 3. doi: 10.1089/jwh.2019.7678. [Epub ahead of print]
3. **Rosberger Z**, Steben M, Norris T, McFadyen A, Shapiro GK. A mixed two-dose vaccination schedule: Not enough evidence to support a policy change in Quebec. *Vaccine*. 2019 Jul 26;37(32):4421. doi: 10.1016/j.vaccine.2019.03.083. No abstract available.
4. Esplen MJ, Hunter J, Maheu C, **Rosberger Z**, Wong J, McGillicuddy P, Secord S, Blacker S, Green E, Toner B, Li J, Dobson K. de Souza interprofessional practice cancer competency framework. *Support Care Cancer*. 2020 Feb;28(2):797-808. doi: 10.1007/s00520-019-04823-z. Epub 2019 May 31.
5. Kesten JM, Flannagan C, Ruane-McAteer E, Merriel SWD, Nadarzynski T, Shapiro G, **Rosberger Z**, Prue G. Mixed-methods study in England and Northern Ireland to understand young men who have sex with men's knowledge and attitudes towards human papillomavirus vaccination. *BMJ Open*. 2019 May 14;9(5):e025070. doi: 10.1136/bmjopen-2018-025070.

6. Henry M, Fuehrmann F, Hier M, Zeitouni A, Kost K, Richardson K, Mlynarek A, Black M, MacDonald C, Chartier G, Zhang X, **Rosberger Z**, Frenkiel S. Contextual and historical factors for increased levels of anxiety and depression in patients with head and neck cancer: A prospective longitudinal study. *Head Neck*. 2019 Aug;41(8):2538-2548. doi: 10.1002/hed.25725. Epub 2019 Mar 19.
7. Tatar O, Shapiro GK, Perez S, Wade K, **Rosberger Z**. Using the precaution adoption process model to clarify human papillomavirus vaccine hesitancy in canadian parents of girls and parents of boys. *Hum Vaccin Immunother*. 2019;15(7-8):1803-1814. doi: 10.1080/21645515.2019.1575711. Epub 2019 Apr 22.
8. Shen S, Zelkowitz P, **Rosberger Z**. Cancer and fertility: optimizing communication between patients and healthcare providers. *Curr Opin Support Palliat Care*. 2019 Mar;13(1):53-58. doi: 10.1097/SPC.0000000000000413. Review.
9. Körner A, Roberts N, Steele RJ, Brosseau DC, **Rosberger Z**. A randomized controlled trial assessing the efficacy of a self-administered psycho-educational intervention for patients with cancer. *Patient Educ Couns*. 2019 Apr;102(4):735-741. doi: 10.1016/j.pec.2018.12.002. Epub 2018 Dec 3.
10. Aubin S, **Rosberger Z**, Hafez N, Noory MR, Perez S, Lehmann S, Batist G, Kavan P. Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. *J Adolesc Young Adult Oncol*. 2019 Apr;8(2):172-189. doi: 10.1089/jayao.2017.0101. Epub 2018 Nov 28.
11. Rodriguez AM, Frenkiel S, Desroches J, De Simone A, Chiocchio F, MacDonald C, Black M, Zeitouni A, Hier M, Kost K, Mlynarek A, Bolster-Foucault C, **Rosberger Z**, Henry M. Development and validation of the McGill body image concerns scale for use in head and neck oncology (MBIS-HNC): A mixed-methods approach. *Psychooncology*. 2019 Jan;28(1):116-121. doi: 10.1002/pon.4918. Epub 2018 Nov 12.
12. Henry M, Alias A, Frenkiel S, Richardson K, Hier M, Zeitouni A, Kost K, Mlynarek A, Black M, MacDonald C, Chartier G, **Rosberger Z**. Contribution of psychiatric diagnoses to extent of opioid prescription in the first year post-head and neck cancer diagnosis: A longitudinal study. *Psychooncology*. 2019 Jan;28(1):107-115. doi: 10.1002/pon.4917. Epub 2018 Nov 5.

### **Nader Sadeghi**

1. **Sadeghi N**, Khalife S, Mascarella MA, Ramanakumar AV, Richardson K, Joshi AS, Bouganim N, Taheri R, Fuson A, Siegel R. Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. *Head Neck*. 2019 Nov 27. doi: 10.1002/hed.26022. [Epub ahead of print]
2. Mascarella MA, Schweitzer L, Alreefi M, Silver J, Caglar D, Loo VG, Richardson K, Dufresne P, Lee TC, **Sadeghi N**. The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy. *J Otolaryngol Head Neck Surg*. 2019 Oct 16;48(1):49. doi: 10.1186/s40463-019-0376-1.
3. Mascarella MA, Milad D, Richardson K, Mlynarek A, Payne RJ, Forest VI, Hier M, **Sadeghi N**, Mayo N. Preoperative Risk Index Among Patients Undergoing Thyroid or Parathyroid Surgery. *JAMA Otolaryngol Head Neck Surg*. 2019 Sep 5. doi: 10.1001/jamaoto.2019.2413. [Epub ahead of print]
4. Mascarella MA, Azzi JL, da Silva SD, Mlynarek A, Forest VI, Hier M, Richardson K, **Sadeghi N**. Postoperative infection predicts poor survival in locoregionally advanced



oral cancer. *Head Neck*. 2019 Oct;41(10):3624-3630. doi: 10.1002/hed.25885. Epub 2019 Aug 5.

5. Benito D, Michel MC, Thakkar PG, Goodman JF, **Sadeghi N**, Joshi AS. A cost effective custom dental guard for transoral robotic surgery. *J Robot Surg*. 2019 Mar 2. doi: 10.1007/s11701-019-00942-1. [Epub ahead of print]
6. Mascarella MA, Richardson K, Mlynarek A, Forest VI, Hier M, Sadeghi N, Mayo N. Evaluation of a Preoperative Adverse Event Risk Index for Patients Undergoing Head and Neck. *Cancer Surgery. JAMA Otolaryngol Head Neck Surg*. 2019 Apr 1;145(4):345-351. doi: 10.1001/jamaoto.2018.4513.

### Jan Seuntjens

1. Renaud J, Sarfehnia A, Bancheri J, **Seuntjens J**. Absolute dosimetry of a 1.5 T MR-guided accelerator-based high-energy photon beam in water and solid phantoms using Aarrow. *Med Phys*. 2019 Dec 13. doi: 10.1002/mp.13968. [Epub ahead of print]
2. Chatterjee A, Serban M, Faria S, Souhami L, Cury F, **Seuntjens J**. Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. *Phys Med*. 2020 Jan;69:36-43. doi: 10.1016/j.ejmp.2019.11.023. Epub 2019 Dec 6.
3. Hijal T, Freeman CR, **Seuntjens J**. Proton beam therapy should remain in the public domain. *CMAJ*. 2019 Nov 18;191(46):E1284. doi: 10.1503/cmaj.73445. No abstract available.
4. Ma CMC, Chetty IJ, Deng J, Faddegon B, Jiang SB, Li J, **Seuntjens J**, Siebers JV, Traneus E. Beam modeling and beam model commissioning for Monte Carlo dose calculation-based radiation therapy treatment planning: Report of AAPM Task Group 157. *Med Phys*. 2020 Jan;47(1):e1-e18. doi: 10.1002/mp.13898. Epub 2019 Nov 19.
5. Renaud J, Palmans H, Sarfehnia A, **Seuntjens J**. Absorbed dose calorimetry. *Phys Med Biol*. 2019 Oct 18. doi: 10.1088/1361-6560/ab4f29. [Epub ahead of print]
6. Rompré-Brodeur A, Shinde-Jadhav S, Ayoub M, Piccirillo CA, **Seuntjens J**, Brimo F, Mansure JJ, Kassouf W. PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: *In Situ* and Abscopal Effects. *Mol Cancer Ther*. 2020 Jan;19(1):211-220. doi: 10.1158/1535-7163.MCT-18-0986. Epub 2019 Sep 18.
7. Aldelaijan S, Devic S, Papaconstadopoulos P, Bekerat H, Cormack RA, **Seuntjens J**, Buzurovic IM. Dose-response linearization in radiochromic film dosimetry based on multichannel normalized pixel value with an integrated spectral correction for scanner response variations. *Med Phys*. 2019 Nov;46(11):5336-5349. doi: 10.1002/mp.13818. Epub 2019 Sep 26.
8. Devic S, Liang L, Tomic N, Bekerat H, Morcos M, Popovic M, Watson P, Aldelaijan S, **Seuntjens J**. Dose measurements nearby low energy electronic brachytherapy sources using radiochromic film. *Phys Med*. 2019 Aug;64:40-44. doi: 10.1016/j.ejmp.2019.05.017. Epub 2019 Jun 22.
9. Kostou T, Papadimitroulas P, Papaconstadopoulos P, Devic S, **Seuntjens J**, Kagadis GC. Size-specific dose estimations for pediatric chest, abdomen/pelvis and head CT scans with the use of GATE. *Phys Med*. 2019 Sep;65:181-190. doi: 10.1016/j.ejmp.2019.08.020. Epub 2019 Sep 5.

10. Ybarra N, **Seuntjens J**. Radio-selective effects of a natural occurring muscle-derived dipeptide in A549 and normal cell lines. *Sci Rep*. 2019 Aug 8;9(1):11513. doi: 10.1038/s41598-019-47944-5.
11. Van der Heggen D, Cooper DR, Tesson M, Joos JJ, **Seuntjens J**, Capobianco JA, Smet PF. Optically Stimulated Nanodosimeters with High Storage Capacity. *Nanomaterials (Basel)*. 2019 Aug 5;9(8). pii: E1127. doi: 10.3390/nano9081127.
12. Monte Carlo simulations of different CT X-ray energy spectra within CTDI phantom and the Tomic N, Papaconstadopoulos P, Bekerat H, Antunovic G, Aldelaijan S, **Seuntjens J**, Devic S. influence of its changes on radiochromic film measurements. *Phys Med*. 2019 Jun;62:105-110. doi: 10.1016/j.ejmp.2019.04.015. Epub 2019 May 11.
13. Zlateva Y, Muir BR, El Naqa I, **Seuntjens JP**. Cherenkov emission-based external radiotherapy dosimetry: I. Formalism and feasibility. *Med Phys*. 2019 May;46(5):2370-2382. doi: 10.1002/mp.13414. Epub 2019 Apr 29.
14. Papaconstadopoulos P, Levesque IR, Aldelaijan S, O'Grady K, Devic S, **Seuntjens J**. Modeling the primary source intensity distribution: reconstruction and inter-comparison of six Varian TrueBeam sources. *Phys Med Biol*. 2019 Jul 2;64(13):135005. doi: 10.1088/1361-6560/ab1ccc.
15. Ayoub M, Shinde-Jadhav S, Mansure JJ, Alvarez F, Connell T, **Seuntjens J**, Piccirillo CA, Kassouf W. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. *Sci Rep*. 2019 Apr 23;9(1):6348. doi: 10.1038/s41598-019-42864-w.
16. Forghani R, Chatterjee A, Reinhold C, Pérez-Lara A, Romero-Sanchez G, Ueno Y, Bayat M, Alexander JWM, Kadi L, Chankowsky J, **Seuntjens J**, Forghani B. Head and neck squamous cell carcinoma: prediction of cervical lymph node metastasis by dual-energy CT texture analysis with machine learning. *Eur Radiol*. 2019 Nov;29(11):6172-6181. doi: 10.1007/s00330-019-06159-y. Epub 2019 Apr 12.
17. Diamant A, Chatterjee A, Vallières M, Shenouda G, **Seuntjens J**. Deep learning in head & neck cancer outcome prediction. *Sci Rep*. 2019 Feb 26;9(1):2764. doi: 10.1038/s41598-019-39206-1.
18. Bancheri J, **Seuntjens J**, Sarfehnia A, Renaud J. Density effects of silica aerogel insulation on the performance of a graphite probe calorimeter. *Med Phys*. 2019 Apr;46(4):1874-1882. doi: 10.1002/mp.13426. Epub 2019 Feb 23.
19. Zlateva Y, Muir BR, **Seuntjens JP**, El Naqa I. Cherenkov emission-based external radiotherapy dosimetry: II. Electron beam quality specification and uncertainties. *Med Phys*. 2019 May;46(5):2383-2393. doi: 10.1002/mp.13413. Epub 2019 Apr 29.
20. Renaud MA, Serban M, **Seuntjens J**. Robust mixed electron-photon radiation therapy optimization. *Med Phys*. 2019 Mar;46(3):1384-1396. doi: 10.1002/mp.13381. Epub 2019 Feb 14.

### George Shenouda

1. Raghavan Nair JK, Vallières M, Mascarella MA, El Sabbagh N, Duchatellier CF, Zeitouni A, **Shenouda G**, Chankowsky J. Magnetic Resonance Imaging Texture Analysis Predicts Recurrence in Patients With Nasopharyngeal Carcinoma. *Can Assoc Radiol J*. 2019 Nov;70(4):394-402. doi: 10.1016/j.carj.2019.06.009. Epub 2019 Sep 11.
2. Eldridge RC, Pugh SL, Trotti A, Hu K, Spencer S, Yom SS, Rosenthal D, Read N, Desai A, Gore E, **Shenouda G**, Mishra MV, Bruner D, Xiao C. Changing functional status

within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. *Head Neck*. 2019 Nov;41(11):3924-3932. doi: 10.1002/hed.25922. Epub 2019 Aug 22.

3. Mell LK, Shen H, Nguyen-Tân PF, Rosenthal DI, Zakeri K, Vitzthum LK, Frank SJ, Schiff PB, Trotti AM 3rd, Bonner JA, Jones CU, Yom SS, Thorstad WL, Wong SJ, **Shenouda G**, Ridge JA, Zhang QE, Le QT. Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. *Clin Cancer Res*. 2019 Dec 1;25(23):7078-7088. doi: 10.1158/1078-0432.CCR-19-1832. Epub 2019 Aug 16.
4. Panet-Raymond V, Sabit K, **Shenouda G**, Sirhan D, Zeitouni A, Souhami L. Growth of Pituitary Macroadenomas Postpartial Resection: Implications for Adjuvant Radiotherapy. *J Neurol Surg B Skull Base*. 2019 Jun;80(3):323-326. doi: 10.1055/s-0038-1670686. Epub 2018 Oct 10.
5. Diamant A, Chatterjee A, Vallières M, **Shenouda G**, Seuntjens J. Deep learning in head & neck cancer outcome prediction. *Sci Rep*. 2019 Feb 26;9(1):2764. doi: 10.1038/s41598-019-39206-1.

### **Sonia Skamene**

1. Yerramilli D, Parker G, LeBaron V, Krishnan M, Hertan L, Spektor A, Shiloh R, **Skamene S**, Balboni T. Ethical issues in patients referred for palliative radiation therapy. *Ann Palliat Med*. 2019 Jul;8(3):231-239. doi: 10.21037/apm.2019.06.02.

### **Susan Solymoss**

1. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Raffi H, **Solymoss S**, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol*. 2019 Oct;20(10):e566-e581. doi: 10.1016/S1470-2045(19)30336-5. Epub 2019 Sep 3. Review.
2. Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, Vanassche T, Verhamme P, Shivakumar S, Gross PL, Lee AYY, Yeo E, **Solymoss S**, Kassis J, Le Tempelier G, Kowalski S, Blostein M, Shah V, MacKay E, Wu C, Clark NP, Bates SM, Spencer FA, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Li N, Moffat KA, Syed S, Schulman S. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. *JAMA Intern Med*. 2019 Aug 5. doi: 10.1001/jamainternmed.2019.2431. [Epub ahead of print]
3. Alcindor T, Al-Fakeeh A, Goulding K, **Solymoss S**, Ste-Marie N, Turcotte R. Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study. *Oncologist*. 2019 Mar;24(3):e111-e114. doi: 10.1634/theoncologist.2018-0081. Epub 2018 Sep 26.

### **Luis Souhami**

1. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M 3rd, Youssef EF, **Souhami L**, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG

- oncology RTOG 0525. *Neurooncol Pract.* 2019 Dec;6(6):473-478. doi: 10.1093/nop/npz006. Epub 2019 Apr 6.
2. Chatterjee A, Serban M, Faria S, **Souhami L**, Cury F, Seuntjens J. Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. *Phys Med.* 2020 Jan;69:36-43. doi: 10.1016/j.ejmp.2019.11.023. Epub 2019 Dec 6.
  3. Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, **Souhami L**, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. *Radiother Oncol.* 2019 Dec;141:137-143. doi: 10.1016/j.radonc.2019.08.020. Epub 2019 Sep 17.
  4. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottvanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; **PORTEC Study Group**. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncol.* 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Erratum in: *Lancet Oncol.* 2019 Sep;20(9):e468.
  5. Ludmir EB, Mahajan A, Ahern V, Ajithkumar T, Alapetite C, Bernier-Chastagner V, Bindra RS, Bishop AJ, Bolle S, Brown PD, Carrie C, Chalmers AJ, Chang EL, Chung C, Dieckmann K, Esiashvili N, Gandola L, Ghia AJ, Gondi V, Grosshans DR, Harrabi SB, Horan G, Indelicato DJ, Jalali R, Janssens GO, Krause M, Laack NN, Laperriere N, Laprie A, Li J, Marcus KJ, McGovern SL, Merchant TE, Merrell KW, Padovani L, Parkes J, Paulino AC, Schwarz R, Shih HA, **Souhami L**, Sulman EP, Taylor RE, Thorp N, Timmermann B, Wheeler G, Wolden SL, Woodhouse KD, Yeboa DN, Yock TI, Kortmann RD, McAleer MF. Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. *Nat Rev Clin Oncol.* 2019 Aug;16(8):521-522. doi: 10.1038/s41571-019-0235-z. No abstract available.
  6. Panet-Raymond V, Sabit K, Shenouda G, Sirhan D, Zeitouni A, **Souhami L**. Growth of Pituitary Macroadenomas Postpartial Resection: Implications for Adjuvant Radiotherapy. *J Neurol Surg B Skull Base.* 2019 Jun;80(3):323-326. doi: 10.1055/s-0038-1670686. Epub 2018 Oct 10.
  7. Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, **Souhami L**, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. *Int J Radiat Oncol Biol Phys.* 2019 Aug 1;104(5):1057-1065. doi: 10.1016/j.ijrobp.2019.03.049. Epub 2019 Apr 6.
  8. Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, **Souhami L**, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM.

- Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. *J Clin Oncol*. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12.
9. Nabid A, **Souhami L**. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. *Eur Urol* 2018;74:432-31. *Eur Urol*. 2019 Mar;75(3):e63. doi: 10.1016/j.eururo.2018.10.029. Epub 2018 Oct 26. No abstract available.
  10. Albeesh R, Turgeon GA, Alfieri J, Mansure JJ, Fu L, Arseneau J, Zeng X, Jardon K, Gilbert L, **Souhami L**. Adjuvant therapy in stage III endometrial cancer confined to the pelvis. *Gynecol Oncol*. 2019 Jan;152(1):26-30. doi: 10.1016/j.ygyno.2018.11.002. Epub 2018 Nov 22.
  11. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, **Souhami L**, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. *J Clin Oncol*. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.
  12. Adil K, Popovic M, Cury FL, Faria SL, Duclos M, **Souhami L**. Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. *Pract Radiat Oncol*. 2019 Jan;9(1):24-28. doi: 10.1016/j.prro.2018.07.006. Epub 2018 Aug 7.
  13. Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, **Souhami L**, Petrecca K, Wenz F. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial.

### Alan Spatz

1. Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, **Spatz A**, Zahedi RP, Sickmann A, Batist G, Borchers CH. Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. *Cancers (Basel)*. 2019 Dec 1;11(12). pii: E1907. doi: 10.3390/cancers11121907.
2. Cheung CC, Barnes P, Bigras G, Boerner S, Butany J, Calabrese F, Couture C, Deschenes J, El-Zimaity H, Fischer G, Fiset PO, Garratt J, Geldenhuys L, Gilks CB, Ilie M, Ionescu D, Lim HJ, Manning L, Mansoor A, Riddell R, Ross C, Roy-Chowdhuri S, **Spatz A**, Swanson PE, Tron VA, Tsao MS, Wang H, Xu Z, Torlakovic EE; Canadian Association of Pathologists-Association Canadienne Des Pathologistes' National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT). Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). *Appl Immunohistochem Mol Morphol*. 2019 Nov/Dec;27(10):699-714. doi: 10.1097/PAI.0000000000000800.

- Garfinkle R, Lee L, Boutros M, Cardin MJ, **Spatz A**, Morin N. Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer *Can J Surg*. 2019 Oct 1;62(5):334-339.
- Wang H, Agulnik J, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, **Spatz A**. Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [*Lung Cancer* 132 (June) (2019) 36-38]. *Lung Cancer*. 2019 Oct;136:161. doi: 10.1016/j.lungcan.2019.08.016. Epub 2019 Aug 25. No abstract available.
- Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, **Spatz A**, Rousseau C, McNamara S, Cohen V, Batist G, Agulnik J. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. *Mol Cancer Ther*. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26.
- Brukner I, Eintracht S, Forgetta V, Papadakis AI, **Spatz A**, Oughton M. Laboratory-developed test for detection of acute *Clostridium difficile* infections with the capacity for quantitative sample normalization. *Diagn Microbiol Infect Dis*. 2019 Oct;95(2):113-118. doi: 10.1016/j.diagmicrobio.2019.04.017. Epub 2019 May 10.
- Wang H, Agulnik J, Kasymjanova G, Fiset PO, Camilleri-Broet S, Redpath M, Cohen V, Small D, Pepe C, Sakr L, **Spatz A**. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. *Lung Cancer*. 2019 Jun;132:36-38. doi: 10.1016/j.lungcan.2019.04.009. Epub 2019 Apr 8. Erratum in: *Lung Cancer*. 2019 Oct;136:161.
- Yip S, Christofides A, Banerji S, Downes MR, Izevbaye I, Lo B, MacMillan A, McCuaig J, Stockley T, Yousef GM, **Spatz A**. A Canadian guideline on the use of next-generation sequencing in oncology. *Curr Oncol*. 2019 Apr;26(2):e241-e254. doi: 10.3747/co.26.4731. Epub 2019 Apr 1.
- Gao ZH, Zorychta E, Karamchandani J, Michel RP, Brimo F, Telleria C, Camilleri-Broët S, Auger M, Nguyen VH, **Spatz A**. Revitalising an academic pathology department: lessons learnt. *J Clin Pathol*. 2019 Mar;72(3):213-220. doi: 10.1136/jclinpath-2018-205516. Epub 2018 Nov 22.

### Barry Stein

- Trépanier M, Valin-Thorburn A, Kouyoumdjian A, Dumitra T, Alhashemi M, Kaneva P, Liberman AS, Charlebois P, **Stein BS**, Fried GM, Feldman LS, Lee L. Intracorporeal versus extracorporeal anastomosis for right colectomy does not affect gastrointestinal recovery within an enhanced recovery after surgery program. *Surg Endosc*. 2019 Oct 23. doi: 10.1007/s00464-019-07204-z. [Epub ahead of print]
- Chau J, Solomon J, Liberman AS, Charlebois P, **Stein B**, Lee L. Pelvic dimensions on preoperative imaging can identify poor-quality resections after laparoscopic low anterior resection for mid- and low rectal cancer. *Surg Endosc*. 2019 Oct 16. doi: 10.1007/s00464-019-07209-8. [Epub ahead of print]
- Trepanier M, Paradis T, Kouyoumdjian A, Dumitra T, Charlebois P, **Stein BS**, Liberman AS, Schwartzman K, Carli F, Fried GM, Feldman LS, Lee L. The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients. *J Gastrointest Surg*. 2020 Jan;24(1):115-122. doi: 10.1007/s11605-019-04328-4. Epub 2019 Jul 31.

4. Karimian N, Kaneva P, Donatelli F, **Stein B**, Liberman AS, Charlebois P, Lee L, Fiore JF Jr, Carli F, Feldman LS. Simple Versus Complex Preoperative Carbohydrate Drink to Preserve Perioperative Insulin Sensitivity in Laparoscopic Colectomy: A Randomized Controlled Trial. *Ann Surg.* 2019 Jul 26. doi: 10.1097/SLA.0000000000003488. [Epub ahead of print]
5. Trepanier M, Alhassan N, Sabapathy CA, Liberman AS, Charlebois P, **Stein BL**, S Feldman L, Lee L. Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective. *Dis Colon Rectum.* 2019 Nov;62(11):1381-1389. doi: 10.1097/DCR.0000000000001438.
6. Mata J, Pecorelli N, Kaneva P, Moldoveanu D, Gosselin-Tardiff A, Alhashemi M, Robitaille S, Balvardi S, Lee L, **Stein BL**, Liberman S, Charlebois P, Fiore JF Jr, Feldman LS. A mobile device application (app) to improve adherence to an enhanced recovery program for colorectal surgery: a randomized controlled trial. *Surg Endosc.* 2020 Feb;34(2):742-751. doi: 10.1007/s00464-019-06823-w. Epub 2019 May 13.
7. Minnella EM, Liberman AS, Charlebois P, **Stein B**, Scheede-Bergdahl C, Awasthi R, Gillis C, Bousquet-Dion G, Ramanakuma AV, Pecorelli N, Feldman LS, Carli F. The impact of improved functional capacity before surgery on postoperative complications: a study in colorectal cancer. *Acta Oncol.* 2019 May;58(5):573-578. doi: 10.1080/0284186X.2018.1557343. Epub 2019 Feb 6.
8. Pecorelli N, Balvardi S, Liberman AS, Charlebois P, **Stein B**, Carli F, Feldman LS, Fiore JF Jr. Does adherence to perioperative enhanced recovery pathway elements influence patient-reported recovery following colorectal resection? *Surg Endosc.* 2019 Nov;33(11):3806-3815. doi: 10.1007/s00464-019-06684-3. Epub 2019 Jan 30.
9. Balvardi S, Pecorelli N, Castelino T, Niculiseanu P, Liberman AS, Charlebois P, **Stein B**, Carli F, Mayo NE, Feldman LS, Fiore JF Jr. Construct Validity and Responsiveness of the Abdominal Surgery Impact Scale in the Context of Recovery After Colorectal Surgery. *Dis Colon Rectum.* 2019 Mar;62(3):309-317. doi: 10.1097/DCR.0000000000001288.
10. Alhashemi M, Fiore JF Jr, Safa N, Al Mahroos M, Mata J, Pecorelli N, Baldini G, Dendukuri N, **Stein BL**, Liberman AS, Charlebois P, Carli F, Feldman LS. Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway. *Surg Endosc.* 2019 Jul;33(7):2313-2322. doi: 10.1007/s00464-018-6514-4. Epub 2018 Oct 17.
11. Alhassan N, Yang M, Wong-Chong N, Liberman AS, Charlebois P, **Stein B**, Fried GM, Lee L. Comparison between conventional colectomy and complete mesocolic excision for colon cancer: a systematic review and pooled analysis : A review of CME versus conventional colectomies. *Surg Endosc.* 2019 Jan;33(1):8-18. doi: 10.1007/s00464-018-6419-2. Epub 2018 Sep 12.
12. Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loïselle SÈ, Liberman AS, **Stein B**, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. *Clin Nutr.* 2019 Jun;38(3):1053-1060. doi: 10.1016/j.clnu.2018.06.982. Epub 2018 Jul 9.

### Gabriela Stroian

1. Fontanarosa D, van der Meer S, Bloemen-van Gorp E, **Stroian G**, Verhaegen F. Magnitude of speed of sound aberration corrections for ultrasound image guided

- radiotherapy for prostate and other anatomical sites. *Med Phys.* 2012 Aug;39(8):5286-92. doi: 10.1118/1.4737571.
- Lee S, **Stroian G**, Kopek N, AlBahhar M, Seuntjens J, El Naqa I. Analytical modelling of regional radiotherapy dose response of lung. *Phys Med Biol.* 2012 Jun 7;57(11):3309-21. doi: 10.1088/0031-9155/57/11/3309. Epub 2012 May 9.
  - Serban M, Heath E, **Stroian G**, Collins DL, Seuntjens J. A deformable phantom for 4D radiotherapy verification: design and image registration evaluation. *Med Phys.* 2008 Mar;35(3):1094-102.
  - Niazi T, Elakshar S, **Stroian G**. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer. *Curr Opin Support Palliat Care.* 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371. Review.
  - Stroian G**, Martens C, Souhami L, Collins DL, Seuntjens J. Local correlation between monte-carlo dose and radiation-induced fibrosis in lung cancer patients. *Int J Radiat Oncol Biol Phys.* 2008 Mar 1;70(3):921-30. doi: 10.1016/j.ijrobp.2007.10.033.
  - Rabinovich A, Bernard L, Ramanakumar AV, **Stroian G**, Gotlieb WH, Lau S, Bahoric B. Para-aortic and pelvic extended-field radiotherapy for advanced-stage uterine cancer: dosimetric and toxicity comparison between the four-field box and intensity-modulated techniques. *Curr Oncol.* 2015 Dec;22(6):405-11. doi: 10.3747/co.22.2727.
  - Conneely E, Alexander A, **Stroian G**, Seuntjens J, Foley MJ. An investigation into the use of MMCTP to tune accelerator source parameters and testing its clinical application. *J Appl Clin Med Phys.* 2013 Mar 4;14(2):3692. doi: 10.1120/jacmp.v14i2.3692.
  - Alexander A, Deblois F, **Stroian G**, Al-Yahya K, Heath E, Seuntjens J. MMCTP: a radiotherapy research environment for Monte Carlo and patient-specific treatment planning. *Phys Med Biol.* 2007 Jul 7;52(13):N297-308. Epub 2007 Jun 6.
  - Stroian G**, Falco T, Seuntjens JP. Elimination of ghost markers during dual sensor-based infrared tracking of multiple individual reflective markers. *Med Phys.* 2004 Jul;31(7):2008-19.

#### **Khalil Sultanem**

- Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, **Sultanem K**, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Eapen L, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. *Lancet Oncol.* 2019 Oct;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3. Epub 2019 Aug 12. Erratum in: *Lancet Oncol.* 2019 Dec;20(12):e663.

#### **Ivan Topisirovic**

- Hipolito VEB, Diaz JA, Tandoc KV, Oertlin C, Ristau J, Chauhan N, Saric A, McLaughlan S, Larsson O, **Topisirovic I**, Botelho RJ. Enhanced translation expands the endo-lysosome size and promotes antigen presentation during phagocyte activation. *PLoS Biol.* 2019 Dec 4;17(12):e3000535. doi: 10.1371/journal.pbio.3000535. eCollection 2019 Dec.



2. Pathria G, Lee JS, Hasnis E, Tandoc K, Scott DA, Verma S, Feng Y, Larue L, Sahu AD, **Topisirovic I**, Ruppin E, Ronai ZA. Translational reprogramming marks adaptation to asparagine restriction in cancer. *Nat Cell Biol.* 2019 Dec;21(12):1590-1603. doi: 10.1038/s41556-019-0415-1. Epub 2019 Nov 18.
3. Ristau J, van Hoef V, Peugeot S, Zhu J, Guan BJ, Liang S, Hatzoglou M, **Topisirovic I**, Selivanova G, Larsson O. RITA requires eIF2 $\alpha$ -dependent modulation of mRNA translation for its anti-cancer activity. *Cell Death Dis.* 2019 Nov 7;10(11):845. doi: 10.1038/s41419-019-2074-3.
4. Lorent J, Kusnadi EP, van Hoef V, Rebello RJ, Leibovitch M, Ristau J, Chen S, Lawrence MG, Szkop KJ, Samreen B, Balanathan P, Rapino F, Close P, Bukczynska P, Scharmann K, Takizawa I, Risbridger GP, Selth LA, Leidel SA, Lin Q, **Topisirovic I**, Larsson O, Furic L. Translational offsetting as a mode of estrogen receptor  $\alpha$ -dependent regulation of gene expression. *EMBO J.* 2019 Dec 2;38(23):e101323. doi: 10.15252/embj.2018101323. Epub 2019 Sep 26.
5. Papadopoli D, Boulay K, Kazak L, Pollak M, Mallette F, **Topisirovic I**, Hulea L. mTOR as a central regulator of lifespan and aging. *F1000Res.* 2019 Jul 2;8. pii: F1000 Faculty Rev-998. doi: 10.12688/f1000research.17196.1. eCollection 2019. Review.
6. Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, **Topisirovic I**, Muller WJ. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. *Nat Commun.* 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.
7. Cargnello M, **Topisirovic I**. c-Myc steers translation in lymphoma. *J Exp Med.* 2019 Jul 1;216(7):1471-1473. doi: 10.1084/jem.20190721. Epub 2019 Jun 17.
8. Oertlin C, Lorent J, Murie C, Furic L, **Topisirovic I**, Larsson O. Generally applicable transcriptome-wide analysis of translation using anota2seq. *Nucleic Acids Res.* 2019 Jul 9;47(12):e70. doi: 10.1093/nar/gkz223.
9. Morita M, Siddiqui N, Katsumura S, Rouya C, Larsson O, Nagashima T, Hekmatnejad B, Takahashi A, Kiyonari H, Zang M, St-Arnaud R, Oike Y, Giguère V, **Topisirovic I**, Okada-Hatakeyama M, Yamamoto T, Sonenberg N. Hepatic posttranscriptional network comprised of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. *Proc Natl Acad Sci U S A.* 2019 Apr 16;116(16):7973-7981. doi: 10.1073/pnas.1816023116. Epub 2019 Mar 29.
10. Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, **Topisirovic I**, Van Rechem C, Mazur PK, Gozani O. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. *Cell.* 2019 Jan 24;176(3):491-504.e21. doi: 10.1016/j.cell.2018.11.038. Epub 2019 Jan 3.
11. Uchenunu O, Pollak M, **Topisirovic I**, Hulea L. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. *J Mol Endocrinol.* 2019 Feb 1;62(2):R83-R103. doi: 10.1530/JME-18-0058. Review.

### Anna Towers

1. Rockson SG, Keeley V, Kilbreath S, Szuba A, **Towers A**. Cancer-associated secondary lymphoedema. *Nat Rev Dis Primers*. 2019 Mar 28;5(1):22. doi: 10.1038/s41572-019-0072-5. Review.
2. Bélanger E, **Towers A**, Wright DK, Chen Y, Tradounsky G, Macdonald ME. Of dilemmas and tensions: a qualitative study of palliative care physicians' positions regarding voluntary active euthanasia in Quebec, Canada. *J Med Ethics*. 2019 Jan;45(1):48-53. doi: 10.1136/medethics-2017-104339. Epub 2018 Oct 30.
3. Hashemi HS, Fallone S, Boily M, **Towers A**, Kilgour RD, Rivaz H. Assessment of Mechanical Properties of Tissue in Breast Cancer-Related Lymphedema Using Ultrasound Elastography. *IEEE Trans Ultrason Ferroelectr Freq Control*. 2019 Mar;66(3):541-550. doi: 10.1109/TUFFC.2018.2876056. Epub 2018 Oct 15.

### Michel Tremblay

1. Giménez-Mascarell P, Oyenarte I, González-Recio I, Fernández-Rodríguez C, Corral-Rodríguez MÁ, Campos-Zarraga I, Simón J, Kostantin E, Hardy S, Díaz Quintana A, Zubillaga Lizeaga M, Merino N, Diercks T, Blanco FJ, Díaz Moreno I, Martínez-Chantar ML, **Tremblay ML**, Müller D, Siliqi D, Martínez-Cruz LA. Structural Insights into the Intracellular Region of the Human Magnesium Transport Mediator CNNM4. *Int J Mol Sci*. 2019 Dec 12;20(24). pii: E6279. doi: 10.3390/ijms20246279.
2. Yue L, Yan M, **Tremblay ML**, Lin TJ, Li H, Yang T, Song X, Xie T, Xie Z. PTP1B negatively regulates nitric oxide-mediated *Pseudomonas aeruginosa* killing by neutrophils. *PLoS One*. 2019 Sep 18;14(9):e0222753. doi: 10.1371/journal.pone.0222753. eCollection 2019.
3. Hardy S, Kostantin E, Wang SJ, Hristova T, Galicia-Vázquez G, Baranov PV, Pelletier J, **Tremblay ML**. Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism. *Proc Natl Acad Sci U S A*. 2019 Feb 19;116(8):2925-2934. doi: 10.1073/pnas.1815361116. Epub 2019 Feb 4.
4. Svensson MN, Doody KM, Schmiedel BJ, Bhattacharyya S, Panwar B, Wiede F, Yang S, Santelli E, Wu DJ, Sacchetti C, Gujar R, Seumois G, Kiesses WB, Aubry I, Kim G, Mydel P, Sakaguchi S, Kronenberg M, Tiganis T, **Tremblay ML**, Ay F, Vijayanand P, Bottini N. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity. *J Clin Invest*. 2019 Mar 1;129(3):1193-1210. doi: 10.1172/JCI123267. Epub 2019 Feb 11.

### Josie Ursini-Siegel

1. Kong T, Ahn R, Yang K, Zhu X, Fu Z, Morin G, Bramley R, Cliffe NC, Xue Y, Kuasne H, Li Q, Jung S, Gonzalez AV, Camilleri-Broët S, Guiot MC, Park M, **Ursini-Siegel J**, Huang S. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. *Cancer Res*. 2019 Nov 13. pii: canres.1108.2019. doi: 10.1158/0008-5472.CAN-19-1108. [Epub ahead of print]
2. Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, **Ursini-Siegel J**, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic

- Vulnerability in H3K27M Gliomas. *Cancer Cell*. 2019 Sep 16;36(3):338-339. doi: 10.1016/j.ccell.2019.08.012. No abstract available.
3. Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, **Ursini-Siegel J**, Basik M, Koromilas AE. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. *Nat Commun*. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.
  4. Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, **Ursini-Siegel J**, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. *Cancer Cell*. 2019 May 13;35(5):782-797.e8. doi: 10.1016/j.ccell.2019.04.004. Erratum in: *Cancer Cell*. 2019 Sep 16;36(3):338-339.

### Marie Vanhuyse

1. Hu J, Aprikian AG, **Vanhuyse M**, Dragomir A. Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. *J Oncol Pract*. 2019 Jun;15(6):e510-e519. doi: 10.1200/JOP.18.00626. Epub 2019 May 20.
2. Lahcene H, Aprikian AG, **Vanhuyse M**, Hu J, Bladou F, Cury F, Kassouf W, Perreault S, Dragomir A. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. *J Oncol Pharm Pract*. 2019 Apr 18:1078155219842329. doi: 10.1177/1078155219842329. [Epub ahead of print]
3. Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, **Vanhuyse M**, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaad S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH. Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). *J Cancer Educ*. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7.

### Tsafir Vanounou

1. Tholomier C, Wang Y, Aleynikova O, **Vanounou T**, Pelletier JS. Biliary mucinous cystic neoplasm mimicking a hydatid cyst: a case report and literature review. *BMC Gastroenterol*. 2019 Jun 24;19(1):103. doi: 10.1186/s12876-019-1001-5. Review.

### Carol-Ann Vasilevsky

1. Garfinkle R, Al-Rashid F, Morin N, Ghitulescu G, Faria J, **Vasilevsky CA**, Boutros M. Are right-sided colectomies for neoplastic disease at increased risk of primary postoperative ileus compared to left-sided colectomies? A coarsened exact matched analysis. *Surg Endosc*. 2019 Dec 11. doi: 10.1007/s00464-019-07318-4. [Epub ahead of print]
2. Garant A, Magnan S, Devic S, Martin AG, Boutros M, **Vasilevsky CA**, Ferland S, Bujold A, DesGroseilliers S, Sebahang H, Richard C, Vuong T. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal

- Cancer. *Int J Radiat Oncol Biol Phys.* 2019 Dec 1;105(5):1005-1011. doi: 10.1016/j.ijrobp.2019.08.042. Epub 2019 Aug 30.
- Alqahtani M, Garfinkle R, Zhao K, **Vasilevsky CA**, Morin N, Ghitulescu G, Faria J, Boutros M. Can we better predict readmission for dehydration following creation of a diverting loop ileostomy: development and validation of a prediction model and web-based risk calculator. *Surg Endosc.* 2019 Aug 26. doi: 10.1007/s00464-019-07069-2. [Epub ahead of print]
  - Abou Khalil M, Bhatnagar SR, Feldman L, Longtin Y, **Vasilevsky CA**, Carignan A, Morin N, Boutros M. Development and validation of a clinical risk calculator for mortality after colectomy for fulminant *Clostridium difficile* colitis. *J Trauma Acute Care Surg.* 2019 Oct;87(4):856-864. doi: 10.1097/TA.0000000000002412.
  - Garfinkle R, Savage P, Boutros M, Landry T, Reynier P, Morin N, **Vasilevsky CA**, Filion KB. Incidence and predictors of postoperative ileus after loop ileostomy closure: a systematic review and meta-analysis. *Surg Endosc.* 2019 Aug;33(8):2430-2443. doi: 10.1007/s00464-019-06794-y. Epub 2019 Apr 17.
  - Abou Khalil M, Abou-Khalil J, Motter J, **Vasilevsky CA**, Morin N, Ghitulescu G, Boutros M. Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database. *J Gastrointest Surg.* 2019 Jun;23(6):1188-1197. doi: 10.1007/s11605-019-04186-0. Epub 2019 Mar 18.
  - Garfinkle R, Lachance S, Vuong T, Mikhail A, Pelsser V, Gologan A, Morin NA, **Vasilevsky CA**, Boutros M. Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy? *Dis Colon Rectum.* 2019 Mar;62(3):294-301. doi: 10.1097/DCR.0000000000001220.
  - Garfinkle R, Abou-Khalil M, Bhatnagar S, Wong-Chong N, Azoulay L, Morin N, **Vasilevsky CA**, Boutros M. A Comparison of Pathologic Outcomes of Open, Laparoscopic, and Robotic Resections for Rectal Cancer Using the ACS-NSQIP Proctectomy-Targeted Database: a Propensity Score Analysis. *J Gastrointest Surg.* 2019 Feb;23(2):348-356. doi: 10.1007/s11605-018-3974-8. Epub 2018 Sep 27.

#### **Antonio Vigano**

- Cyr C, Arboleda MF, Aggarwal SK, Balneaves LG, Daeninck P, Néron A, Prosk E, **Vigano A**. Erratum to cannabis in palliative care: current challenges and practical recommendations. *Ann Palliat Med.* 2019 Apr;8(2):215-217. doi: 10.21037/apm.2019.01.06. Epub 2019 Feb 13. No abstract available.
- Kasvis P, Vigano M, **Vigano A**. Health-related quality of life across cancer cachexia stages. *Ann Palliat Med.* 2019 Jan;8(1):33-42. doi: 10.21037/apm.2018.08.04. Epub 2018 Sep 5. Review.

#### **Té Vuong**

- Garant A, Magnan S, Devic S, Martin AG, Boutros M, Vasilevsky CA, Ferland S, Bujold A, DesGroseilliers S, Sebahang H, Richard C, **Vuong T**. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer. *Int J Radiat Oncol Biol Phys.* 2019 Dec 1;105(5):1005-1011. doi: 10.1016/j.ijrobp.2019.08.042. Epub 2019 Aug 30.
- Shoemaker T, **Vuong T**, Glickman H, Kaifi S, Famulari G, Enger SA. Dosimetric Considerations for Ytterbium-169, Selenium-75, and Iridium-192 Radioisotopes in High-

- Dose-Rate Endorectal Brachytherapy. *Int J Radiat Oncol Biol Phys*. 2019 Nov 15;105(4):875-883. doi: 10.1016/j.ijrobp.2019.07.003. Epub 2019 Jul 19.
3. Devic S, Bekerat H, Garant A, **Vuong T**. Optimization of HDRBT boost dose delivery for patients with rectal cancer. *Brachytherapy*. 2019 Jul - Aug;18(4):559-563. doi: 10.1016/j.brachy.2019.02.001. Epub 2019 Mar 23.
  4. Popescu T, Karlsson U, Vinh-Hung V, Trigo L, Thariat J, **Vuong T**, Baumert BG, Motta M, Zamagni A, Bonet M, Myint AS, Lara PC, Nguyen NP, Arenas M. Challenges Facing Radiation Oncologists in The Management of Older Cancer Patients: Consensus of The International Geriatric Radiotherapy Group. *Cancers (Basel)*. 2019 Mar 16;11(3). pii: E371. doi: 10.3390/cancers11030371.
  5. Garfinkle R, Lachance S, **Vuong T**, Mikhail A, Pelsser V, Gologan A, Morin NA, Vasilevsky CA, Boutros M. Is the Pathologic Response of T3 Rectal Cancer to High-Dose-Rate Endorectal Brachytherapy Comparable to External Beam Radiotherapy? *Dis Colon Rectum*. 2019 Mar;62(3):294-301. doi: 10.1097/DCR.0000000000001220.

#### Peter Watson

1. Devic S, Liang L, Tomic N, Bekerat H, Morcos M, Popovic M, **Watson P**, Aldelaijan S, Seuntjens J. Dose measurements nearby low energy electronic brachytherapy sources using radiochromic film. *Phys Med*. 2019 Aug;64:40-44. doi: 10.1016/j.ejmp.2019.05.017. Epub 2019 Jun 22. PubMed PMID: 31515034.

#### Michael Witcher

1. Jangal M, Lebeau B, **Witcher M**. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy? *Expert Opin Ther Targets*. 2019 Jul;23(7):565-578. doi: 10.1080/14728222.2019.1627329. Epub 2019 Jun 10.
2. Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, Foulkes WD, **Witcher M**. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. *Cancer Res*. 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.
3. Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, **Witcher M**, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. *Nat Commun*. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
4. Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, **Witcher M**, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma *In Situ*. *Cancer Res*. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
5. Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, Alaoui-Jamali M, **Witcher M**. Oncogenic

activity of poly (ADP-ribose) glycohydrolase. *Oncogene*. 2019 Mar;38(12):2177-2191. doi: 10.1038/s41388-018-0568-6. Epub 2018 Nov 20.

6. Busch CM, Prickett JT, Stein R, Cuoco JA, Marvin EA, **Witcher MR**. Meckel Cave Epidermoid Cyst Presenting as Multiple Cranial Nerve Deficits Due to Indirect Tumoral Compression of the Cavernous Sinus: A Case Report and Literature Review. *World Neurosurg*. 2019 Jan;121:88-94. doi: 10.1016/j.wneu.2018.09.206. Epub 2018 Oct 9. Review.

### Norma Ybarra

1. **Ybarra N**, Seuntjens J. Radio-selective effects of a natural occurring muscle-derived dipeptide in A549 and normal cell lines. *Sci Rep*. 2019 Aug 8;9(1):11513. doi: 10.1038/s41598-019-47944-5.

### George Zogopoulos

1. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, **Zogopoulos G**, Bouganim N, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatology*. 2019 Dec 14. pii: S1424-3903(19)30807-5. doi: 10.1016/j.pan.2019.12.010. [Epub ahead of print]
2. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, **Zogopoulos G**, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. Cancer Risks Associated With Germline *PALB2* Pathogenic Variants: An International Study of 524 Families. *J Clin Oncol*. 2019 Dec 16;JCO1901907. doi: 10.1200/JCO.19.01907. [Epub ahead of print]
3. Chen YI, Callichurn K, Chatterjee A, Desilets E, Fergal D, Forbes N, Gan I, Kenshil S, Khashab MA, Kunda R, Lam E, May G, Mohamed R, Mosko J, Paquin SC, Sahai A, Sandha G, Teshima C, Barkun A, Barkun J, Bessissow A, Candido K, Martel M, Miller C, Waschke K, **Zogopoulos G**, Wong C; ELEMENT trial and for the Canadian Endoscopic Research Collaborative (CERC). ELEMENT TRIAL: study protocol for a randomized controlled trial on endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs. endoscopic retrograde cholangio-

- pancreatography in the management of malignant distal biliary obstruction. *Trials*. 2019 Dec 9;20(1):696. doi: 10.1186/s13063-019-3918-y.
4. Miller CS, Chen YI, Haito Chavez Y, Alghamdi A, **Zogopoulos G**, Bessissow A. Double-balloon endoscopic ultrasound-guided gastroenterostomy: simplifying a complex technique towards widespread use. *Endoscopy*. 2020 Feb;52(2):151-152. doi: 10.1055/a-0991-7530. Epub 2019 Sep 17. No abstract available.
  5. Wong C, Chen F, Alirezaie N, Wang Y, Cuggia A, Borgida A, Holter S, Lenko T, Domecq C; Alzheimer's Disease Neuroimaging Initiative, Petersen GM, Syngal S, Brand R, Rustgi AK, Cote ML, Stoffel E, Olson SH, Roberts NJ, Akbari MR, Majewski J, Klein AP, Greenwood CMT, Gallinger S, **Zogopoulos G**. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. *PLoS Genet*. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.
  6. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, **Zogopoulos G**, Bouganim N, Guo K, Rogado J, Martin E, Alcindor T, Colomer R. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. *Pancreas*. 2019 May/Jun;48(5):e45-e47. doi: 10.1097/MPA.0000000000001294. No abstract available.
  7. Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters BG, O'Kane GM, Wilson JM, **Zogopoulos G**, Notta F, Knox JJ, Gallinger S. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. *Cancer Cell*. 2019 Feb 11;35(2):267-282.e7. doi: 10.1016/j.ccell.2018.12.010. Epub 2019 Jan 24.
  8. Hallet J, Jayaraman S, Martel G, Ouellet JB, Lin Y, McCluskey S, Beyfuss KA, Karanicolas PJ; **Canadian Hepato-Pancreatico-Biliary Association group**. Patient blood management for liver resection: consensus statements using Delphi methodology. *HPB (Oxford)*. 2019 Apr;21(4):393-404. doi: 10.1016/j.hpb.2018.09.022. Epub 2018 Nov 13.